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ABSTRACT 
 In order to eradicate HIV-1 infection the virus needs to be specifically eliminated 
from latently infected memory CD4
+
 T cells. There does not seem to be a single 
mechanism that promotes HIV-1 latency. RNA Polymerase II (RNAP II) pausing, 
chromatin structure, tissue specific transcriptional repressors and transcriptional 
interference have been implicated in regulating HIV-1 transcription. The transcription 
factor B Lymphocyte-Induced Maturation Protein 1 (Blimp-1) is expressed in B and T 
cells and upregulated in patients chronically infected with HIV-1. I hypothesized that 
Blimp-1 is a T cell intrinsic factor that binds to HIV-1 LTR, inhibits HIV-1 transcription 
and contributes to HIV-1 latency. Blimp-1 is expressed in primary peripheral blood CD4
+
 
T cells and is further induced by T cell activation. Importantly, Blimp-1 is highly 
expressed in memory CD4
+
 T cells compared to naïve CD4
+
 T cells. Ectopic expression 
of Blimp-1 in CD4
+
 T cells represses HIV-1 transcription, whereas decreasing Blimp-1 in 
memory CD4
+
 populations activates HIV-1 transcription. Reduction of Blimp-1 in 
infected primary T cells increases RNAP II processivity and histone H3 acetylation. 
Blimp-1 binds downstream of the HIV-1 5’-LTR to the interferon-stimulated response 
  vii 
element (ISRE) in resting primary CD4
+
 T cells and strongly represses Tat-dependent 
HIV-1 transcription. Upon T cell activation, Blimp-1 is released from the HIV-1 ISRE 
and this correlates with significant increase in HIV-1 transcription. These results 
demonstrate that Blimp-1 acts to limit HIV-1 transcription in memory CD4
+
 T cells and 
promotes the establishment and maintenance of latency. I also examined whether 
neighboring host promoters could impact HIV-1 transcription. Using a set of inducible 
cell lines I observed that neighboring promoters have minimal impact on HIV-1 
transcription and that enabling release of paused RNAP II by diminishing negative 
elongation factor (NELF) is sufficient to reactivate transcriptionally repressed HIV-1 
provirus. The implications of my results in the different mechanisms regulating HIV-1 
latency are discussed. 
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I.  Introduction 
 
1.  Epidemiology of Human Immunodeficiency Virus 
 
Infection with human immunodeficiency virus type 1 (HIV-1) leads to the 
development of Acquired Immunodeficiency Syndrome (AIDS), a disease whose 
hallmark is a decline in CD4
+
 T cells and an increased susceptibility to opportunistic 
infections and cancer. In addition to directly impacting the number of CD4
+
 T cells, HIV-
1 infection leads to indirect immune exhaustion by activating neighboring or bystander 
cells and results in a general imbalance of all T cell populations, facilitating the immune 
dysregulation associated with AIDS (Chevalier and Weiss, 2013; Moreno-Fernandez et 
al., 2012; Paiardini and Muller-Trutwin, 2013). HIV-1 is a zoonotic disease that resulted 
from cross-species transmission of simian immunodeficiency virus (SIV) naturally 
infecting African non-human primates (Sharp and Hahn, 2011). HIV-1 is transmitted via 
bodily fluids and the life expectancy without treatment is 9 to 11 years (Programme and 
(UNAIDS), 2014). HIV-1 was first identified as a causative agent of AIDS in 1983 
(Barre-Sinoussi et al., 1983; Gallo et al., 1983) but the first HIV-1 infection dates back to 
the 1920s (Faria et al., 2014). In 2013 the number of people living with HIV-1 worldwide 
reached an estimated 35 million (Programme and (UNAIDS), 2014) (Fig. 1). There were 
approximately 2.1 million new HIV-1 infections and 1.5 million AIDS-related deaths in 
2013 (Fig. 1) (Programme and (UNAIDS), 2014). Although the disease has plateaued in 
the recent years due to treatment options and public health efforts, there is still no cure 
for HIV-1/AIDS.   
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The current combination therapy, called Highly Active Antiretroviral Therapy 
(HAART), was available to only 12.9 million people in 2013 (36.9% of infected people) 
(Fig. 1) (Programme and (UNAIDS), 2014). Drugs used in HAART target viral fusion, 
reverse transcription, integration and maturation of the virus. HAART does not inhibit 
viral transcription or release and because it targets viral proteins (with the exception of 
entry inhibitors) the virus mutates to escape the drugs action and develops resistance. In 
addition, HAART has many side effects and does not reverse the inflammation and 
premature aging associated with HIV-1 infection even when viral load is undetectable. 
 
  
 
 
 
 
Figure 1. HIV-1 Epidemic in Numbers (based on UNSAIDS data). 
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2.  Human Immunodeficiency Virus 
 
 Virion Structure 
HIV-1 is a retrovirus belonging to the Lentivirus genus. It is a single-stranded, 
positive-sense, enveloped RNA virus. The hexameric p24 capsid (CA) protein forms a 
cone-shaped core which encloses two copies of viral RNA genome in complex with the 
p7 nucleocapsid (NC) protein, as well as the accessory proteins Tat and Rev. The capsid 
is surrounded by the p17 matrix (MA) protein which assembles into trimers. The outer 
surface of the HIV-1 membrane is a lipid bilayer derived from host cell during viral 
budding that is studded with envelope spikes composed of gp120 and gp41 trimers. The 
HIV-1 virion also contains three enzymes, reverse transcriptase, integrase and protease, 
enclosed inside the capsid, as well as accessory proteins Nef, Vpr and Vif (Fig. 2).  
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HIV-1 Genome  
 The genome of integrated HIV-1 provirus is 9719 base pairs long and is flanked at 
each end by long terminal repeats (LTRs) (Fig. 3). The 5’-LTR serves as the viral 
promoter and transcriptional enhancer. The genes encoded by HIV-1 are as follow:  
- gag – encodes the precursor polyprotein Pr55Gag which is cleaved by viral 
protease into MA, CA, NC, and p6, as well as two spacer peptides, SP1, and SP2. 
MA, CA and NC are structural proteins and the expression of Gag in the absence 
Lipid 
membrane 
(host-derived) 
Matrix 
(MA) 
Viral envelope 
(gp120/gp41 trimer) 
Capsid 
(CA) 
Nucleocapsid 
(NC) 
Host cell protein 
Viral 
RNA 
Reverse 
Transcriptase 
(RT) 
Integrase 
(IN) 
Protease 
(PR) 
 Figure 2. Structure of Human Immunodeficiency Virus. 
The HIV-1 virion contains two copies of single-stranded, positive-sense RNA which 
interact closely with the nucleocapsid. The RNA together with three viral enzymes, 
protease, reverse transcriptase and integrase, is enclosed in viral capsid. The viral 
capsid is surrounded by matrix which in turn is surrounded by lipid bilayer derived 
from the host PM. The lipid membrane is embedded with host cell proteins and is 
studded with viral envelope spikes which are composed of trimers of gp120 and 
gp41. 
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of other viral proteins and RNA genome is sufficient for the production of non-
infectious virus-like particles (VLPs). p6 is required for incorporation of Vpr into 
the HIV-1 virions and contains late domain motifs necessary for virus budding 
(Garrus et al., 2001). 
- pol – encodes Pol polyprotein processed into HIV-1 protease, reverse 
transcriptase and integrase. HIV-1 protease cleaves viral polyproteins (Gag and 
Pol) and thus is required for viral maturation. HIV-1 reverse transcriptase is 
responsible for transcribing viral RNA into DNA, while HIV-1 integrase is 
required for integration of HIV-1 DNA into host genome (Sierra et al., 2005). 
- env – encodes the viral envelope polyprotein gp160 which is spliced into gp120 
and gp41. gp120 binds to CD4 receptor and CXCR4 or CCR5 co-receptors 
enabling insertion of gp41 into PM, which in turn leads to viral fusion with the 
target cell (Postler and Desrosiers, 2013). The cytoplasmic domain of gp41 also 
contains signaling motifs that can activate NFκB, which is important for HIV-1 
transcription (Postler and Desrosiers, 2013). 
- tat – encodes cell membrane-permeable Tat (trans-activator of transcription), 
which binds to trans-activation response (TAR) RNA stemloop and recruits p-
TEFb to initiate HIV-1 transcripion (Watson and Edwards, 1999). Tat is cell 
membrane permeable (Watson and Edwards, 1999). 
- rev – encodes Rev (Regulator of Expression of Virion Proteins), a protein 
required for viral mRNA splicing and export from the nucleus (Pollard and 
Malim, 1998). 
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- nef – encodes Nef (negative regulatory protein) which is important in 
modulating host cell signaling and reponses. The expression of Nef alone in 
animal models results in AIDS-like symptoms (Rahim et al., 2009). 
- vif – encodes Vif (viral infectivity factor), a protein that increases viral 
infectivity by targeting APOBEC-3G, a cytidine deaminase (deanimates cytidine 
into uridine0, for proteasomal degradation (Goila-Gaur and Strebel, 2008). 
- vpr – encodes Vpr (viral protein R) , a protein that induces cell cycle arrest in 
CD4
+
 T cells and facilitates infection of macrophages by unknown mechanisms 
(Li et al., 2009).  
vpu – encodes Vpu (viral protein U) important for viral budding by targeting 
tetherin for proteasomal degradation (Kueck and Neil, 2012).  
 
 
 
 
Figure 3. Organization of Human Immunodeficiency-1 Virus Genome. 
HIV-1 genome has LTR at each of its ends that serve as viral promoter and 
enhancer. HIV--1 encodes gag, pol and env polyproteins, as well as accessory 
proteins: Tat, Vif, Vpr, Vpu, Rev and Nef. 
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3.  Replication Cycle of HIV-1 
 
HIV-1 replication cycle is composed of the following steps: virus binding, fusion, 
uncoating, reverse transcription, integration, transcription, translation, assembly and 
budding (Fig. 4). Upon the binding of the HIV-1 envelope to CD4 receptor and a 
chemokine co-receptor expressed at the surface of the target cell, the viral fusion peptide 
penetrates host plasma membrane (PM) and then the virion fuses with the PM or with 
endosomal compartment (Postler and Desrosiers, 2013). In the cytoplasm the viral core 
disassembles and viral RNA is reverse transcribed into double-stranded cDNA bythe 
viral reverse transcriptase. The uncoating of the virion might be blocked by TRIM5α 
(Yan and Chen, 2012). Reverse transcription is blocked by such host-restriction factors as 
APOBEC-3G (Yan and Chen, 2012), a cytidine deaminase that deaminates cytidine to 
uridine in the viral DNA during the process of reverse transcription, SAMHD1, which 
hydrolyzes dNTPs and degrades viral RNA (Yang and Greene, 2014) and TREX, an 
exonuclease digesting excessive HIV-1 DNA (Yan et al., 2010). Recent studies show that 
RNA polymerase II-associated factor 1 (PAF1) inhibits early steps of viral replication 
leading to decreased reverse transcription and proviral integration (Liu et al., 2011). The 
viral cDNA is imported to the nucleus by preintegration complex (PIC) and is integrated 
into the host genome by viral integrase. Lens epithelium-derived growth factor (LEDGF) 
binds to chromosomal DNA and HIV-1 integrase and favors HIV-1 integration into 
LEDGF-regulated, A-T-rich genes, while integrase interactor 1 (INI1) facilitates HIV-1 
integration by remodeling nucleosomes (Ciuffi et al., 2005; Lesbats et al., 2011).  The 
provirus is next transcribed by host transcriptional machinery into RNA. While the 
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multiply spliced viral RNAs encoding for Tat, Rev and Nef are processed by the cellular 
splicing and nuclear export machinery, the unspliced viral RNA genome and singly-
spliced viral mRNAs (encoding Gag, Env, Vif, Vpr and Vpu) are transported to 
cytoplasm, a process controlled by the viral protein Rev (Felber et al., 1989). The 
envelope is synthesized on the rough endoplasmic reticulum (ER) and is transported 
through the ER to Golgi and trans-Golgi network (TGN) (Saftig and Klumperman, 2009). 
Gag is synthesized by membrane-unattached ribosomes (Perlman and Resh, 2006). 
Newly synthesized Gag accumulates in the perinuclear region, and before reaching the 
PM it passes through a late endosome-like compartment (Klein et al., 2007; Perlman and 
Resh, 2006). Gag is responsible for targeting HIV-1 to lipid rafts in host plasma 
membrane (PM) by binding to phosphatidylinositol-4,5-bisphosphate (PIP2) (Klein et al., 
2007). The MA domain targets Gag to the PM via the 14-carbon-long N-myristyl group 
at the glycine 2 position, and the basic region at the amino-terminal end (Klein et al., 
2007). Gag binds to the genomic RNAs, and together with the envelope assembles into 
HIV-1 virions, which then bud off the cell (Klein et al., 2007; Postler and Desrosiers, 
2013). The budding of HIV-1 is blocked by such host factors as tetherin, ISG15, miRNA, 
TIM-1, TIM-3 and TIM-4 (Chen et al., 2014; Li et al., 2014; Pincetic et al., 2010; Yan 
and Chen, 2012). HIV-1 matures by cleavage of the Gag precursor, Pr55Gag, by viral 
protease into MA, CA, NC, and p6, as well as two spacer peptides, SP1 and SP2. 
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4.  HIV-1 Persistence During Therapy 
 
HAART is a combination of several antiviral drugs that target viral fusion, 
reverse transcription, integration and maturation of HIV-1. A remaining challenge in 
efforts to cure HIV-1 infection is targeting cells harboring quiescent, yet replication-
competent virus. HAART and host immune system do not affect latently-infected cells 
which are the source of viral rebound after cessation of antiretroviral treatments 
(Richman et al., 2009; Siliciano and Greene, 2011). Upon cessation of HAART, HIV-1 
rapidly reemerges from latently infected cells to pretreatment viral loads (Fig. 5) 
(Richman et al., 2009; Siliciano and Greene, 2011). HIV-1 preferentially infects activated 
CD4
+
 T cells. HIV-1 infection either leads to productive HIV-1 replication and cell death 
or to the transition of effector cell into a memory CD4
+
 T cell and establishment of 
latency. Memory CD4
+
 T cells are considered the main reservoir of latent HIV-1. The 
latently infected cells persist for the life of an infected individual. In addition to memory 
CD4
+
 T cells, other latent reservoirs are thought to exist. Using dual-reporter virus 
Figure 4. HIV-1 Replication Cycle. 
The HIV-1 virion binds via gp120 to its receptor, CD4, and co-receptor, CCR5 or 
CXCR4. The binding is followed by fusion of the virion with the target cell which is 
mediated by gp41. Next the viral core undergoes uncoating and RNA genome is 
reversly transcribed into dsDNA., which is next imported into the nucleus. In the 
nucleus viral integrase mediates interation of HIV-1 into host genome. The provirus 
is transcribed, the viral mRNAs spliced and exported into the cytoplasm where they 
are translated by free polysomes or in ER. The viral proteins and mRNA are 
transported to the PM. The virus assembles and buds off from lipid rafts. The 
maturation of HIV-1 involves cleaving of Pr55Gag by viral protease. For a more 
detailed description of each step in the HIV-1 replication cycle please see the text. 
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expressing one HIV-1 LTR-dependent marker to measure productive HIV-1 infection, 
and a second marker under a constitutive promoter independent of HIV-1 LTR it has 
been shown that HIV-1 establishes latency even in activated CD4
+
 T cells (Calvanese et 
al., 2013). Strategies to target latent reservoir requires characterizing the cell populations 
that harbor latent HIV-1 and understanding the biochemical mechanisms that regulate 
provirus expression in these cells.  
The size of a latently-infected viral reservoir is still a matter of debate (Stevenson, 
2013). Originally, based on the ability to grow virus from blood samples in vitro (viral 
outgrowth assay), the size of latent reservoir was estimated to be 1 cell in a million. 
However, recent studies have suggested that the size of latent reservoir is at least 60-fold 
higher than previously thought (Ho et al., 2013). Plus, exactly what cells and tissues 
harbor latent infected cells has made it difficult to accurately measure the total size of the 
viral reservoir in vivo. It has been also estimated that the latent reservoir must be reduced 
by more that 10,000-fold to cure HIV-1 infection (Hill et al., 2014).  
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The establishment of latent reservoir occurs within the first 3 days of SIV 
infection (Whitney et al., 2014). Studies using dual fluorescent reporter virus that allows 
detection of infected cells independent of transcription from HIV-1 LTR confirm that the 
majority of virus becomes latent shortly after infection and that it can be reactivated 
(Dahabieh et al., 2013). Thus, initiation of HAART as early as possible increases the 
chances of not only stopping viremia but also decreasing the possibility of viral rebound 
(Whitney et al., 2014). The “Mississippi Baby” who was perinatally infected with HIV-1 
Figure 5. HIV-1 Clinical Progression. Modified from (Fauci et al., 1996) 
During the acute infection the viral load rapidly increases while the number of CD4
+
 T 
cells falls drastically. Once the patient initiates HAART, which targets actively 
replicating virus, the viral load decreases to even undetectable levels, while the number 
of CD4
+
 T cells recovers, but not to the pre-treatment levels. However, treatment 
interruption results in a reemergence of virus from latently infected cells to high pre-
treatment levels. The latently infected cells harbor replication-competent virus that is not 
actively transcribed until some signal triggers its reactivation. Without treatment the 
infection may result in AIDS which is characterized by high viral loads and CD4
+
 T cell 
numbers below 200 cells /mm
3
 which makes the patient susceptible to opportunistic 
infections and results in death. 
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and who within 30 hours after birth was put on HAART for 18 months did not have a 
viral rebound for over 2 years after cessation of treatment (Ledford, 2014). In contrast, 
“Boston patients”, whose viremia was actively suppressed by HAART prior to receiving 
bone marrow transplants to repopulate hematopoietic cells had viral rebound within a few 
months of HAART interruption (Henrich et al., 2014) suggesting that early treatment 
might diminish but not completely suppress virus reservoir establishment and is 
associated with positive prognosis.  
 
5.  Molecular Mechanisms of HIV-1 Latency 
 
The mechanisms that establish HIV-1 latency remain incompletely defined and 
research has focused on general events that control gene expression including 
transcription initiation, elongation and epigenetic regulation of chromatin (Richman et 
al., 2009; Schiralli Lester and Henderson, 2012; Siliciano and Greene, 2011). HIV-1 
latency is driven by transcriptional repression; however there does not seem to be a single 
mechanism that promotes HIV-1 latency. RNA Polymerase II (RNAP II) pausing, 
chromatin structure and recruitment of ubiquitously expressed transcription factors as 
well as non-coding RNAs have been implicated in the regulation of HIV-1 transcription. 
Additionally, T cell specific factors may be repressing HIV-1 transcription in memory 
CD4
+
 T cells, the major reservoir of latent HIV-1. Transcriptional interference from 
neighboring host promoters is also thought to contribute to establishing and maintaining 
HIV-1 latency (Fig. 6).  
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Additionally, HIV-1 latency can be a stochastic process, where the virus enters 
latency and gets reactivated regardless of T cell activation level (Ho et al., 2013). The 
presence of Tat has been shown to inhibit the establishment of HIV-1 latency (Donahue 
et al., 2012). Superinfection with HIV-1 results in Tat-dependent reactivation of latent 
virus, suggesting that limiting amounts of Tat drive HIV-1 latency (Donahue et al., 
2013). Strategies targeting signals which regulate recruitment of transcription factors, 
chromatin remodeling complexes or regulators of RNAP II have been devised to activate 
and purge HIV-1 latent reservoirs (Deeks et al., 2012; Lafeuillade, 2012; Margolis and 
Hazuda, 2013; Richman et al., 2009; Siliciano and Greene, 2011; Tyagi and Bukrinsky, 
2012).  
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5.1 Transcription Factors 
 
HIV-1 LTR controls provirus transcription by functioning as a promoter and 
enhancer recruiting host transcription factors and co-activators necessary to initiate 
transcription. HIV-1 LTR has three binding sites for the specificity protein 1 (Sp1) and 
two binding sites for the nuclear factor κB (NFκB). Binding of Sp1 and NFκB to HIV-1 
LTR, as well as their physical interaction is required for robust HIV-1 transcription 
(Perkins et al., 1993). In addition to Sp1, NFκB acts in synergy with the activator protein 
1 (AP1), a heterodimer of c-Fos and c-Jun, to induce HIV-1 transcription (Yang et al., 
1999). HIV-1 LTR also contains three binding sites for CCAAT-enhancer-binding 
proteins (C/EBP) (Tesmer et al., 1993), which although not required, enhance basal and 
active HIV-1 transcription in macrophages (Henderson and Calame, 1997; Henderson et 
Figure 6. Model for HIV-1 Transcriptional Regulation. 
During initiation of HIV-1 transcription RNAP II is recruited to HIV--1 LTR and 
transcribes nascent TAR RNA.  However, transcriptional repressors bind to HIV--1 LTR 
and NELF forms a complex with RNAP II, DSIF and Pcf11 resulting in paused RNAP II 
at HIV--1 LTR. Additionally, methyltransferases and HDACs condense chromatin 
making it inaccessible to the transcriptional machinery. All these events are cooperative 
and combinatorial. Upon cell stimulation, transcriptional activators and enhancers are 
recruited to HIV--1 LTR, Tat binds to TAR RNA and recruits P-TEFb which activates 
RNAP II by phosphorylating its CTD. P-TEFb also phosphorylates NELF and DSIF. 
Phosphorylated NELF dissociates from RNAP II, while phosphorylation of DSIF 
changes it from transcriptional repressor to transcriptional activator. Histone modifying 
factors remodel and remove methyl groups from Nuc-1 making the chromatin more 
accessible to the transcriptional machinery. DSIF and Pcf11, which is required for 
transcript termination, travel down the provirus with RNAP II. For a more detailed 
description of HIV-1 transcription please see the text. 
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al., 1995). Upon cell activation, the transcription factor II human (TFIIH) gets recruited 
to HIV-1 LTR where it phosphorylates CTD of RNAP II enabling HIV-1 reactivation 
(Kim et al., 2006). T cell stimulation also activates RBF2, a complex composed of USF-
1, USF-2 and TFII-I to enhance HIV-1 transcription (Chen et al., 2005). Ets-1 stably 
binds to HIV-1 LTR 1 and physically interact with NFκB, NFAT and USF-1 to induce 
HIV-1 transcription (Bassuk et al., 1997; Gegonne et al., 1993; Seth et al., 1993; Sieweke 
et al., 1998). A subset of T cell transcription factors have been suggested to rapidly 
reactivate latent HIV-1 (Kaczmarek et al., 2013).  NFAT was considered critical for 
overcoming latency and induction of HIV-1 transcription in different T cell subsets 
(Dahabieh et al., 2011; Malcolm et al., 2008), although recent studies have questioned its 
role in the reactivation of latent HIV-1 (Bosque and Planelles, 2009; Kinoshita et al., 
1998; Pessler and Cron, 2004; Robichaud et al., 2002). 
HIV-1 LTR also can be bound by transcriptional repressors and contains negative 
regulatory element (NRE) between -420 and -154 of HIV-1 LTR which mediates 
inhibition of HIV-1 transcription (Rosen et al., 1985; Siekevitz et al., 1987). p50 
homodimers, a subunit of NFκB, bind to HIV-1 LTR and recruit histone deacetylase 1 
(HDAC1), which in turn decreases histone acetylation and recruitment of RNAP II 
repressing proviral transcription (Williams et al., 2006). p50 can also form heterodimers 
with E2F1 protein which repress NFκB-induced HIV-1 transcription (Kundu et al., 1997). 
Yin Yang 1 (YY1) has been shown to recruit HDAC1 to a positioned Nucleosome-1 
(Nuc-1) adjacent to the HIV-1 transcriptional start site, to decrease histone H4 acetylation 
at Nuc-1, and to co-operate with LSF to represses HIV-1 (He and Margolis, 2002; 
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Margolis et al., 1994; Romerio et al., 1997). However, recent studies showed that 
decreasing YY1 re-activates latent HIV-1 without affecting the recruitment of HDACs or 
the levels of acetylated histone H3 (Barton and Margolis, 2013). C-promoter binding 
factor-1 (CBF-1), a heterochromatin marker, represses HIV-1 transcription by inhibiting 
recruitment of RNAP II and acetylation of Nuc-1 (Tyagi and Karn, 2007). The T cell 
commitment factor B-cell lymphoma 11b (Bcl-11b, also known as CTIP-2) (Liu et al., 
2010) binds HIV-1 LTR and limits transcription by binding Tat and redirecting it to 
heterochromatic regions (Le Douce et al., 2012; Marban et al., 2007; Rohr et al., 2003). 
 
 
5.2 RNA Polymerase II Promoter Proximal Pausing 
 
RNAP II pausing is defined by stalling of the RNAP II at a promoter and is a a 
critical checkpoint in controlling gene transcription (Gaertner et al., 2012; Rahl et al., 
2010). RNAP II pausing is characterized by the accumulation of short initiated mRNA 
transcripts but lack of transcriptional elongation. RNAP II pausing may be beneficial for 
the transcription of a gene, as deletion of eleven-nineteen lysine-rich leukemia (ELL), 
which facilitates RNAP II pause site entry, results in loss of P-TEFb recruitment to pre-
initation complex and disrupts elongation (Byun et al., 2012). Negative elongation factor 
(NELF) and DRB sensitivity-inducing factor (DSIF) induce promoter-proximal pausing 
of RNAP II (Wada et al., 1998a; Yamaguchi et al., 1999). DSIF is a heterodimer 
composed of hSpt4 and hSpt5 that interacts with RNAP II and nascent RNA. NELF is 
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composed of four subunits (NELF-A, NELF-B, NELF-C/D and NELF-E) and binds to 
pre-formed DSIF-RNAP II complexes (Narita et al., 2003; Yamaguchi et al., 2002). P-
TEFb, a heterodimer of Cdk9 and cyclin T1, phosphorylates C-terminal domain (CTD) of 
RNAP II activating it and releasing the pause induced by NELF and DSIF (Fujinaga et 
al., 2004; Peterlin and Price, 2006; Wada et al., 1998b; Yamaguchi et al., 1999). P-TEFb 
also phosphorylates NELF-E causing its release and hSpt5 subunit of DSIF, switching 
DSIF to a stimulator of RNAP II processivity (Fujinaga et al., 2004; Ivanov et al., 2000; 
Wada et al., 1998a; Yamada et al., 2006). P-TEFb can be brought to poised genes by 
bromodomain-containing protein 4 (Brd4), which recruits it from the repressive 
7SK/HEXIM1 complex composed of 7SK small nuclear RNA (snRNA), HEXIM, 
LARP7 and MEPCE (Jang et al., 2005; Krueger et al., 2008; Yang et al., 2005). CDK7 is 
a subunit of TFIIH that recruits DSIF to promoters inducing RNAP II pausing, and that is 
also required for P-TEFb-mediated phosphorylation enabling transcriptional elongation 
(Larochelle et al., 2012). In addition, Gdown-1 inhibits transcriptional initiation by TFIIF 
(Cheng et al., 2012). TRIM28 has been recently implicated in regulating RNAP II 
pausing at mammalian genes (Bunch et al., 2014). Nonphosphorylated TRIM28 at S824 
stabilizes paused RNAP II, while S824-phosphorylated TRIM28 is required for release of 
paused RNAP II (Bunch et al., 2014). c-Myc is another factor required for the release of 
paused RNAP II (Rahl et al., 2010). While these cellular factors have been shown to be 
necessary for general transcription from host promoters, roles in HIV-1 LTR-mediated 
transcription have still not been confirmed for all. 
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In latently-infected cells, transcription of HIV-1 provirus is inhibited at the step of 
transcription elongation. NELF binds at HIV-1 LTR to RNAP II/DSIF complex inducing 
RNAP II promoter proximal pausing (Zhang et al., 2007). NELF also recruits Pcf11 and 
NCoR1-GPS2-HDAC3 complex to HIV-1 LTR which results in premature termination of 
transcription and condensed chromatin, respectively (Natarajan et al., 2013). Recently, 
the microprocessor complex composed of RNase III Drosha and the dsRNA-binding 
protein Dgcr8 has been shown not only to cleave the 5' stem loop RNA structure, TAR, 
but also to recruit Setx, Xrn2, and Rrp6 leading to RNAP II stalling at HIV-1 LTR 
(Wagschal et al., 2012). Setx and Xrn2 are transcription termination factors mediating 
premature termination of transcription, while Rpr6 processes cleaved TAR RNAs to 
repress HIV-1 transcription (Wagschal et al., 2012). To overcome RNAP II promoter 
proximal pausing, HIV-1 encodes a transcriptional activator, Tat, which via cyclin-
dependent kinase substrate 1 (NUCKS1)-dependent mechanism binds TAR RNA (Kim et 
al., 2014) and gets activated by the lysine methyltransferase Set7/9-KMT7 (Pagans et al., 
2010). Cyclin T1-associated Tat recruits AF4/FMR2 family member 1 (AFF1)/P-TEFb 
complexes (Lu et al., 2014a) to HIV-1 LTR that are normally sequestered away by 
HEXIM1–7SK snRNA regulatory complex (du Chene et al., 2007; Garber et al., 1998; 
Wei et al., 1998). P-TEFb alleviates transcriptional repression by phosphorylating 
components of the paused RNAP II complex including the CTD of RNAPII facilitating 
productive transcription elongation (Isel and Karn, 1999). Protein phosphatase 1A 
(PPM1A) is present at high levels in resting CD4
+
 T cells and inhibits P-TEFb activation 
by preventing CKD9 T-loop  phosphorylation, which in turn leads to repression of HIV-1 
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transcription (Budhiraja et al., 2012). In addition, Brd4 competes with Tat for binding to 
P-TEFb (Bisgrove et al., 2007). The splicing-associated c-Ski-interacting protein, SKIP, 
binds to Tat/P-TEFb complexes, and together with c-Myc and Menin transactivates Tat, 
as well as promotes transcriptional elongation of HIV-1 (Bres et al., 2005; Bres et al., 
2009). The Super Elongation Complex (SEC) composed of P-TEFb, Eleven-Nineteen 
Lysine-Rich Leukemia (ELL2), AFF1, AF4/FMR2 Family Member 4 (AFF4), eleven-
nineteen-leukemia (ENL), and ALL1-fused gene from chromosome 9 protein (AF9) 
binds to RNAP II and promotes efficient elongation (He et al., 2011). 
 
 
5.3 Chromatin Structure 
 
Regardless of the integration site the 5’ end of HIV-1 provirus is associated with 
Nucleosome-0 (Nuc-0) and Nuc-1 (Verdin et al., 1993). Nuc-0 is positioned upstream of 
5’-HIV-1 LTR, while Nuc-1 is located directly downstream of the HIV-1 LTR at 
approximately 100 nt after the transcription start site (TSS) and is better studied in 
regulation of HIV-1 transcription than Nuc-0 (Verdin et al., 1993). Histones can be post-
translationally modified by acetylation, methylation, phosphorylation and ubiquitination. 
Factors associated with the HIV-1 LTR recruit histone acetyltransferases (HATs) and 
KDM demethylases that regulate chromatin organization of the integrated provirus 
(Schiralli Lester and Henderson, 2012). HATs such as p300/CBP and P/CAF, are 
recruited by Tat to acetylate not only histones but also NF-κB (Deng et al., 2001; Furia et 
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al., 2002). However, transcriptional repressors are also recruited to HIV-1 LTR, such as 
methyltransferases including SUV39H1 (du Chene et al., 2007), G9a (Imai et al., 2010), 
GLP (Ding et al., 2013) and enhancer of Zeste 2 (EZH2) (Friedman et al., 2011), as well 
as HDACs (Keedy et al., 2009), which methylate and deacetylate histones, respectively, 
within positioned nucleosomes favoring condensation of chromatin and making the 
proviral LTR less accessible for efficient transcription. HDAC2 and HDAC3 have been 
shown to be present in the nuclei of latent cells and to repress HIV-1 transcription (Keedy 
et al., 2009). In microglial cells Bcl-11b recruits HDAC1, HDAC2, and SUV39H1 to 
HIV-1 LTR resulting in deacetylation and methylation of Nuc-1 (Marban et al., 2007). 
Furthermore, Bcl-11b facilitates binding of heterochromatin protein 1 (HP1) (Marban et 
al., 2007). In addition, CpG methylation of the 5’-HIV-1 LTR by methyl-CpG binding 
domain protein 2 (MBD2) is not required for the establishment of HIV-1 latency, but has 
been associated with increased resistance to reactivation (Blazkova et al., 2009; Kauder et 
al., 2009). BRG1-associated factors (BAF), a member of switching-defective-sucrose 
non-fermenting (SWI/SNF) family, represses HIV-1 transcription by re-positioning Nuc-
1closer to the HIV-1 LTR (Rafati et al., 2011). PBAF, another member of (SWI/SNF 
family), gets recruited by Tat and enables remodeling of Nuc-1 and transcriptional 
elongation (Easley et al., 2010; Rafati et al., 2011). USF-1 co-operates with Sp1, NF-kB 
and LEF-1 to remove histone NH(2) tails from DNA (Angelov et al., 2000). Integration 
of HIV-1 close to nuclear bodies containing promyelocytic leukemia protein (PML) is 
associated with increased H3K9me2-metylation mediated by the methyltransferase G9a 
and thus increased latency (Lusic et al., 2013). Overall, these multiple posttranslational 
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changes of histones contribute to coordinated mechanism that can positively and 
negatively influence the epigenetic state of HIV-1. 
 
 
5.4 Influence of Neighboring Promoters 
 
Three-fourths of HIV-1 provirus preferentially integrates into introns of actively 
transcribed host genes (Ding et al., 2013; Lenasi et al., 2008; Lewinski et al., 2005; Shan 
et al., 2011; Sherrill-Mix et al., 2013). Transcriptional interference is thought to occur 
when HIV-1 integrates next to a gene with stronger promoter. HIV-1 can integrate in 
three orientations relative to the host gene: parallel or tandem, convergent and divergent 
orientation (Fig. 7). Transcriptional interference has been shown to suppress gene 
expression, especially when the genes are in a convergent or parallel orientation 
(Eszterhas et al., 2002). In the parallel orientation scenario, RNAP II from the upstream 
gene reads through HIV-1 LTR displacing its transcriptional machinery (Fig. 7) (Lenasi 
et al., 2008). The inhibition of transcription from the upstream promoter can induce HIV-
1 transcription in the parallel orientation (Lenasi et al., 2008). In the convergent 
orientation the two transcriptional machineries from two promoters are thought to collide 
leading to transcriptional interruption of both genes (Fig. 7). In the divergent orientation 
scenario the two promoters may be competing for limited quantities of transcriptional 
activators and RNAP II (Fig. 7). The integration site of provirus has been shown to not 
only affect the transcriptional activity of provirus (Jordan et al., 2001), but also the 
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persistence and expansion of HIV-1-infected cells (Maldarelli et al., 2014). For example, 
integration of provirus into introns of BACH2 and MKL2 in the same transcriptional 
orientation correlates with clonal expansion and persistence of infected cells (Ikeda et al., 
2007; Maldarelli et al., 2014). Early studies showed that transcriptional interference is 
strongest in the convergent orientation, while it has the weakest influence when 
promoters are in a divergent orientation (Eszterhas et al., 2002). The integration site 
played the strongest role on transcriptional activity in the parallel orientation (Eszterhas 
et al., 2002).  
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 Additionally, numerous antisense RNA (asRNA) transcripts that may originate 
from transcriptional interference have been identified which might also regulate HIV-1 
transcription and replication (Landry et al., 2007; Michael et al., 1994). In addition, HIV-
1 LTR has been also implicated in the generation of asRNAs (Bentley et al., 2004; 
Peeters et al., 1996), which have been shown to halt viral transcription (Kobayashi-
Ishihara et al., 2012; Tagieva and Vaquero, 1997). A recent study detected antisense 
protein (ASP) which is encoded by a region in the minus strand env gene, and which 
regulates HIV-1 replication by inducing autophagy (Torresilla et al., 2013). 
 
 
5.5 T Cell Transcription Factors Implicated in Regulation of HIV-1 Transcription 
 
CD4
+
 effector T cell subsets possess diverse specialized functions. CD4
+
 T helper 
cells (TH1, TH2, TH17) are responsible for the production of cytokines stimulating 
specific immune responses, follicular B helper T cells (TFH) support B cell activation, 
regulatory T cells (Treg) suppress immune responses elicited by CD4
+
, CD8
+
 T cells and 
Figure 7. Potential Role of Transcriptional Interference in HIV-1 Transcription 
HIV-1 can integrate in three different orientations relative to the host gene: convergent, 
parallel and divergent. In the convergent orientation the RNAP IIs from the two 
promoters collide leading to termination of transcription. In the parallel orientation the 
RNAP II from the upstream host gene reads through HIV--1 LTR leading to occlusion 
and dissociation of transcription factors from the viral promoter. In divergent orientation 
the two promoters are competing for limiting amounts of transcriptional activators and 
RNAP II. 
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B cells, while memory T cells are important for the recall of immune response (Murphy 
and Stockinger, 2010; van Leeuwen et al., 2009; Zhu et al., 2010). During infection 
antigen presenting cells (APC) display antigenic peptides in the context of MHC II to 
naïve CD4
+
 T cells (TH0), promoting their clonal expansion and polarization into effector 
T cells. A subset of activated CD4
+
 cells will generate memory T cells responsible for 
rapid recall of the adaptive immune response upon re-exposure. The differentiation of 
CD4
+
 T cells is driven in part by avidity of T cell receptor (TCR) engagement, strength of 
signaling, co-stimulatory signals and tissue microenvironments which include cytokine 
milieu and differential interactions with APC (Fig. 8) (Zhu et al., 2010). Additionally, 
CD4
+
 T cell development is controlled by a constellation of transcription factors that 
activate and repress batteries of genes that influence proliferation, differentiation and 
lineage commitment (Murphy and Stockinger, 2010; van Leeuwen et al., 2009; Yamane 
and Paul, 2013).  
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Although all CD4
+
 T cells are susceptible to HIV-1 infection due to their 
expression of CD4 and chemokine receptors, CXCR4 and CCR5, the ability of different 
T cell populations to support HIV-1 replication varies (Chevalier and Weiss, 2013; 
Figure 8. Model of Sequential CD4
+
 T Cell Differentiation. Modified from 
(Kaczmarek et al., 2013) 
Upon activation by antigen presenting cell (APC), naïve T cell (TH0) undergoes 
differentiation into effector or memory populations. The different effector populations 
have capacity to mature into effector memory T cells (TEM). Stem cell memory T cells 
(TSCM), follicular helper T cells (TFH) and regulatory T cells (Treg) mature into central 
memory T cells (TCM), which then can become transitional memory T cells (TTM) and 
further convert into TEM. 
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Moreno-Fernandez et al., 2012; Paiardini and Muller-Trutwin, 2013), possibly reflecting 
differential expression of T cell-specific transcription factors that regulate HIV-1 
expression. It is possible that these T cell factors, by promoting HIV-1 transcription, 
influence the dissemination of virus at different stages of AIDS or, by repressing proviral 
transcription contribute to the establishment of latently infected T cells. By targeting 
CD4
+
 effector T cells, HIV-1 has a dramatic impact on the depletion, expansion and 
function of the different polarized T cell subsets. The maturation of T cell lineages is in 
part driven by intrinsic transcription factors which potentially influence how efficiently 
HIV-1 replicates (Table 1). Quiescent memory CD4
+
 T cells have been implicated as the 
primary HIV-1 reservoir because they are susceptible to HIV-1 infection, are long-lived 
and, with their ability to self-renew, potentially maintain pools of latently infected cells. 
Whether there are T cell specific factors that predispose memory cells to latent HIV-1 
infection has not been demonstrated. 
The polarization of TH1 verses TH2 cells is mediated by two primary transcription 
factors, T-bet and GATA-3, respectively, whereas RORγt facilitates the differentiation of 
TH17 cells (Amsen et al., 2009; Muranski and Restifo, 2013; Zhu et al., 2010). TH1 cells 
have been reported to be limited in their ability to support HIV-1 replication, although 
there is no evidence that T-bet, the TH1 master transcription factor, directly influences 
HIV-1 transcription (Gosselin et al., 2010). T-bet antagonizes GATA-3 function, which is 
considered the key regulator of TH2 differentiation (Amsen et al., 2009; Kanhere et al., 
2012; Zhu et al., 2010). GATA-3 binds to several sites in the HIV-1 LTR and induces 
HIV-1 transcription (Galio et al., 1997; Yang and Engel, 1993). Therefore, T-bet 
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potentially limits HIV-1 transcription by targeting GATA-3. In addition to GATA-3, c-
Maf promotes TH2 differentiation (Ho et al., 1998) and, in regards to HIV-1 transcription, 
binds HIV-1 LTR and cooperates with NF-κB and NFAT to enhance HIV-1 transcription 
(Zhang et al., 2012). The ability of GATA-3 and c-Maf to activate HIV-1 transcription is 
consistent with findings that TH2 cells support HIV-1 replication (Gosselin et al., 2010; 
Zhang et al., 2012). TH17 cells also support robust HIV-1 replication (Rodriguez-Garcia 
et al., 2014), although RORγt and RORc, factors which are abundant in TH17 cells 
(Gosselin et al., 2010), have not been shown to directly impact HIV-1 transcription. Thus, 
induction of downstream T cell signaling pathways that culminate in activation of NF-
κB, NFAT and STATs probably strongly influence HIV-1 transcription in TH17 cells. 
There has been recent interest in characterizing the role of Treg cells in HIV-1 
(Chevalier and Weiss, 2013; Moreno-Fernandez et al., 2012). In general, changes in Treg 
numbers and function have been documented in patients and include higher Treg 
frequencies in untreated AIDS patients and diminished ability of these cells to suppress 
immune activation in HAART treated patients (Chevalier and Weiss, 2013; Moreno-
Fernandez et al., 2012). Whether these changes are a direct result of HIV-1 infection or 
reflect more general immune dysfunction requires further investigation. Treg development 
is in part driven by the transcription factor FoxP3 (Zhu et al., 2010). The data as to 
whether FoxP3 directly impacts HIV-1 transcription are conflicting. Ectopically 
expressed FoxP3 in primary CD4
+
 T cells inhibits activation and recruitment of 
transcriptional activators NF-κB, CREB and NFAT2 to the LTR (Grant et al., 2006; 
Selliah et al., 2008). FoxP3 may also facilitate HIV-1 transcription by inhibiting HDAC1 
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(Holmes et al., 2011; Holmes et al., 2007). However, overexpression of FoxP3 in 
different T cell subsets may result in different transcriptional outcomes. For example, 
forced expression of FoxP3 polarized naïve CD4
+
 T cells towards a Treg phenotype and 
enhanced HIV-1 replication, but had no impact on T memory cell phenotypes or HIV-1 
transcription (Oswald-Richter et al., 2004). These conflicting results may reflect intrinsic 
differences of T cell subsets or challenges associated with overexpressing factors, and 
underscore the need to further study HIV-1 transcription in primary Treg cells. 
A unique feature of the adaptive immune response is the generation of memory. 
For CD4
+
 T cells two distinct memory populations have been well characterized based on 
the expression of surface markers, homing capacity and function upon reactivation; T 
central memory (TCM) and T effector memory (TEM) cells (Pepper and Jenkins, 2011; 
Sallusto et al., 2004; van Leeuwen et al., 2009). Recently, stem cell memory T cells 
(TSCM) have been described in humans (Gattinoni et al., 2011). These self-renewing 
memory CD4
+
 cells are reported to generate T memory and effector populations. The 
array of factors, including cytokines, signaling events and transcription factors, that 
influence the proliferation and generation of TSCM, TCM and TEM have not been fully 
elucidated. Critical transcription factors that regulate the generation and survival of TCM 
include Schnurri-2, STAT3, STAT5a TBR2, FOXO3a, Bmi1 and LKLF (Catalfamo et 
al., 2008; Hirschhorn-Cymerman et al., 2012; Juffroy et al., 2010; Kimura et al., 2007; 
Kuo et al., 1997; van Grevenynghe et al., 2008; Yamashita et al., 2008). Furthermore, 
Bach-2, IRF-1 and p27 (Kip1) have been suggested to suppress TEM differentiation 
(Jatzek et al., 2012; McElligott et al., 1997; Tsukumo et al., 2013b). Relevant to HIV-1, 
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memory cells, especially TCM and TSCM, have been implicated as primary reservoirs 
harboring latent provirus because they are susceptible to HIV-1 infection, long-lived and, 
with their ability to self-renew, may maintain and/or renew the pool of cells harboring 
latent provirus (Bosque et al., 2011; Buzon et al., 2014). This homeostatic proliferation of 
infected TCM and TSCM in the absence of T cell activation and robust HIV-1 transcription 
presents a major barrier to eradicating persistent HIV-1 infection and underscores the 
need to characterize the tissue distribution and factors that regulate these different T cell 
memory subsets (Henrich and Gandhi, 2013). The predisposition for HIV-1 to establish 
latency in TCM may reflect the expression levels of transcription factors; TCM express T-
bet (Marshall et al., 2011) and have lower levels of Cyclin T1 and phosphorylated CDK9, 
the two subunits of P-TEFb required for transcription elongation (Budhiraja et al., 2013), 
whereas, TEM have increased expression of factors shown to activate HIV-1 transcription 
including GATA-3, c-Maf and RORγt. (Dutta et al., 2013; Wang et al., 2010) The 
discrepancy of what key check points limit HIV-1 transcription in latently infected cells 
may reflect heterogeneity of memory cells, difference in cell culture conditions and 
isolation of cell subsets. The factors that repress transcription in T memory cells have not 
been defined but most likely include epigenetic factors such as HDACs or 
methyltransferases (Richman et al., 2009; Siliciano and Greene, 2011). 
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Table 1. Factors Influencing CD4
+ 
T Cells Differentiation and HIV-1 Transcription. 
 
Transcription 
Factor 
T Cell 
Subset 
Promoted 
T Cell 
Subset 
Inhibited 
Effect on 
HIV-1 
Transcription 
Reference 
Bcl-6 TFH, TCM TH2 Inhibition, 
Activation (?) 
(Baron et al., 1997; Ichii et 
al., 2007; Pepper et al., 
2011; Sawant et al., 2013; 
Yu et al., 2009) 
Bcl-11b 
(CTIP-2) 
All  Inhibition (Le Douce et al., 2012; Liu 
et al., 2010; Marban et al., 
2007; Rohr et al., 2003) 
Blimp-1  TH1, 
TH17, TFH 
Repression, 
Activation 
(Cimmino et al., 2008; 
Johnston et al., 2012; Lin et 
al., 2014) 
BRG1 TH1, TH2  Activation & 
Inhibition 
(Agbottah et al., 2006; 
Henderson et al., 2004; 
Rafati et al., 2011; Wurster 
and Pazin, 2008; Zhang and 
Boothby, 2006) 
c-Maf TH2, TFH, 
TEM 
TH1 Activation (Ho et al., 1998; Kroenke et 
al., 2012; Sato et al., 2011; 
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Zhang et al., 2012) 
c-Myb TH2, TEM  Activation (Dasgupta et al., 1990; 
Kozuka et al., 2011; Nakata 
et al., 2010) 
CIITA TH2 (?)  Activation & 
Inhibition (?) 
(Okamoto et al., 2000; 
Otten et al., 2003; 
Saifuddin et al., 2000; Sung 
and Simon, 2004) 
CREB TH1, Treg  Activation (Rabbi et al., 1997a; Rabbi 
et al., 1997b; Ruan et al., 
2009; Yao et al., 2013) 
CTCF TH1, TH2  Inhibition (Li et al., 2008; Ribeiro de 
Almeida et al., 2009; 
Sekimata et al., 2009) 
Ets-1 TH1, Treg TH17 Activation (Gegonne et al., 1993; 
Grenningloh et al., 2005; 
Moisan et al., 2007; Mouly 
et al., 2010) 
FoxP3 Treg  Activation & 
Inhibition (?) 
(Chen et al., 2003; Grant et 
al., 2006; Holmes et al., 
2011; Holmes et al., 2007; 
Selliah et al., 2006) 
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GATA3 TH2, TEM TH1 Activation (Yang and Engel, 1993; 
Zheng and Flavell, 1997) 
IRF-1 TH1 TEM Activation (Lohoff et al., 1997; 
Sgarbanti et al., 2002; Taki 
et al., 1997) 
IRF-8  TH17 Inhibition (Ouyang et al., 2011; 
Sgarbanti et al., 2002) 
JunB TH2, Treg  Activation (Blonska et al., 2012; 
Roebuck et al., 1996; Son 
et al., 2011) 
JunD  TH1, TH2 Activation (Meixner et al., 2004; 
Roebuck et al., 1996) 
Lef1 Treg  Activation (Fu et al., 2012; Sheridan et 
al., 1995) 
Menin TH17  Activation (Bres et al., 2009; 
Watanabe et al., 2014) 
NFAT TH1,  Treg TH2 Activation (Cron et al., 2000; Ranger 
et al., 1998; Tone et al., 
2008; Wu et al., 2006) 
PU.1 TH9, 
memory 
TH2, Treg Activation (Chang et al., 2009; Chang 
et al., 2010; Hadjur et al., 
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TH9 2009; Lodie et al., 1998) 
SATB1 TH2, Treg  Inhibition (Fu et al., 2012; Kumar et 
al., 2005; Notani et al., 
2010) 
SIRT1  Treg Activation & 
Inhibition 
(Pagans et al., 2005; van 
Loosdregt et al., 2010; 
Zhang and Wu, 2009) 
SMAD3 TH2, Treg, 
TEM,  TH9 
TH1, 
TH17 
Activation (Blokzijl et al., 2002; 
Coyle-Rink et al., 2002; 
Elyaman et al., 2012; 
Giroux et al., 2011; Hu et 
al., 2012; Xiao et al., 2008; 
Zhang et al., 2013) 
SMAD4 TH1, Treg  Inhibition (Coyle-Rink et al., 2002; 
Huss et al., 2011; Yang et 
al., 2008b) 
STAT1 TH1, Treg, 
TFH 
 Activation & 
Inhibition 
(Chang et al., 2002; Choi et 
al., 2013; Ouaked et al., 
2009; Owaki et al., 2005) 
STAT3 TFH, TH17, 
TH1,  TH2, 
TCM 
Treg Unknown (Ma et al., 2012; Owaki et 
al., 2008; Sawant et al., 
2013; Siegel et al., 2011a; 
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Sundaravaradan et al., 
2010; Wei et al., 2008) 
STAT5 TH2, Treg, 
TCM 
TH1, TFH, 
TH17 
Activation & 
Inhibition 
(Burchill et al., 2007; Crotti 
et al., 2007; Della Chiara et 
al., 2011; Johnston et al., 
2012; Laurence et al., 2007; 
Riou et al., 2007; Selliah et 
al., 2006; Takatori et al., 
2005; Zhu et al., 2003) 
T-bet TH1 Treg,  TH2 Unknown (Lazarevic et al., 2011; 
Lugo-Villarino et al., 2003; 
Mullen et al., 2001) 
TRAF-2  TH2 Activation (Horie et al., 2007; 
Lieberson et al., 2001; 
Tsitsikov et al., 1997) 
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5.6 B Lymphocyte-Induced Maturation Protein 1 
 
The Prdm1 gene located on chromosome 6q21 encodes B lymphocyte-induced 
maturation protein-1 (Blimp-1), a 789 amino acid-long, weighting 87,990 Da, nuclear 
transcription factor (Martins and Calame, 2008). Blimp-1 is comprised of N-terminal 
acidic domain, PRDI-BF1-RIZ1 homologous (PR) domain, proline-rich domain (PRD), 
five Kruppel-like (C2H2) zinc-fingers and another acidic domain at C-terminus (Fig. 9). 
The PRD interacts with Grucho family proteins (Ren et al., 1999), the lysine demethylase 
LSD1 (Su et al., 2009) and HDAC2 (Yu et al., 2000). Full length Blimp-1 is called 
Blimp-1α, while Blimp-1 lacking PR domain is called Blimp-1β. Even though Blimp-1β 
binds the same genes as full length Blimp-1, it has attenuated ability to repress them 
(Gyory et al., 2003). The C-terminal C2H2 zinc-fingers contain a nuclear localization 
signal and mediate binding to DNA (Martins and Calame, 2008), as well as recruitments 
of the SET domain histone methyltransferase G9a (Gyory et al., 2004) and the arginine 
methyltransferase Prmt5 (Ancelin et al., 2006). The N-terminal PR domain and two 
acidic domains of Blimp-1 have been also shown to be critical in repression of gene 
transcription and can act independently of each other (Yu et al., 2000).  
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Blimp-1 is critical for the differentiation of mature B cells into long-lived, Ig-secreting 
plasma cells and has been recently demonstrated to be expressed in dendritic cells, 
macrophages, keratinocytes and T cells (Chan et al., 2009; Chang et al., 2000; Chiang et 
al., 2013; Kim et al., 2011; Lin et al., 2002; Lin et al., 1997; Magnusdottir et al., 2007; 
Shaffer et al., 2002; Shapiro-Shelef et al., 2003; Smith et al., 2011; Turner et al., 1994). 
In T cells Blimp-1 regulates the activation and generation of CD4 and CD8 T cell 
effector populations (Hua et al., 2013; Kallies et al., 2006; Kallies et al., 2009; Martins et 
al., 2006) (Fig. 10). Blimp-1 inhibits both T cell proliferation and differentiation into TFH 
(Crotty et al., 2010). Murine CD4
+
 T cells express high Blimp-1 levels in effector and 
memory subsets and minimal Blimp-1 expression in TH0 cells (Savitsky et al., 2007) 
(Table 2). In addition to its role in the differentiation of immune cells, Blimp-1 plays a 
crucial role in limb, pharynx and heart morphogenesis (Bikoff et al., 2009).  
Figure 9. Blimp-1 Structure. Modified from (Martins and Calame, 2008) 
Blimp-1 proteins is composed of two acidic regions, one PR domain, one proline-rich 
domain and five zinc-fingers. The zinc-fingers mediate the binding of Blimp-1 to DNA. 
The proline-rich region has been shown to interact with methyltransferases and histone 
deacetylases and to recruit them to Blimp-1 target-genes. The acidic and PR domains 
have also been shown to be involved in Blimp-1-mediated transcription. 
  
38 
 
 
   
Phase T Cell Subset Blimp-1 Levels 
Naïve TH0 + 
Effector TH1, TH2, TH17, Treg 
TFH 
+++ 
+ 
Memory TCM, TTM, TEM ++ 
 
Blimp-1 represses the transcription of several regulatory factors including Bcl-6, 
T-bet, IL-2, IL-6, TNFα, IFN-γ, IFN-β and type-III IFNs while enhancing the expression 
of IL-10 and Mcl-1 (Chan et al., 2009; Cimmino et al., 2008; Iwasaki et al., 2013; Keller 
and Maniatis, 1991; Lin et al., 2007; Martins et al., 2008; Smith et al., 2010; Swider et 
Figure 10. Role of Blimp-1 in Immune Cell Differentiation. Modified from (Crotty et 
al., 2010) 
Blimp-1 is important regulator of differentiation and maturation of immune cells. 
Overexpression of Blimp-1 in B cells causes them to differentiation into long-lived, Ig-
secreting plasma cells. Blimp-1 is expressed at different levels in CD4
+
 T cell subsets and 
represses the differentiation of TFH. In CT8
+
 T cells the expression of Blimp-1 causes 
them to differentiate into cytotoxic T cells. 
 
Table 2. Expression of Blimp-1 in Murine CD4
+
 T Cell Subsets. 
 
 
 
 
 
 
 
Modified from (Savitsky et al., 2007) 
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al., 2014). Blimp-1-deficient DCs secret significantly higher amounts of IL-6 and CCL2, 
and favor the differentiation of TFH (Chan et al., 2009; Kim et al., 2011). Blimp-1 also 
plays an important role in innate immunity by activating granzyme B, murine p202, a 
cytosolic DNA-sensor that inhibits AIM2 inflammasome formation, and repressing 
AIM2, and NLRP-12 (Gong and Malek, 2007; Lord et al., 2009; Panchanathan et al., 
2012; Yin et al., 2013) (Fig. 11). 
 
 
Listeria monocytogenes, Escherichia coli, Staphylococcus aureus, Sendai virus 
and LPS induce Blimp-1 expression in bone marrow–derived macrophages (Severa et al., 
2014). Blimp-1 is regulated by several mechanisms in different cell types.  It is induced 
by IL-2, IL-21, OX40, STAT3, STAT5, IRF5, IFN-α, PPARγ, RXRα and TLR9 (Boettler 
Figure 11. Blimp-1 is a Global Transcriptional Regulator. 
Blimp-1 represses a constellation of genes in different cell types. However, Blimp-1 has 
been also shown to induce transcription of some genes. 
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et al., 2013; Garcia-Bates et al., 2009; Genestier et al., 2007; Hodge et al., 2012; Lien et 
al., 2010; Nurieva et al., 2012; Panchanathan et al., 2012; Parlato et al., 2013) and 
inhibited by RIG-I (Sathe et al., 2014) and Bach2, a transcription factor suppressing 
CD4
+
 T cell differentiation (Tsukumo et al., 2013a) (Fig. 12).
 
 
In the context of HIV-1, Blimp-1 expression is increased in chronically infected 
patients but remains unaltered in long term non-progressors and correlates with enhanced 
expression of negative regulators of T cell activation including PD-1, LAG3 and CTLA-
4, and with T cell exhaustion and apoptosis (Che et al., 2012; de Masson et al., 2014; 
Seddiki et al., 2013; Shankar et al., 2011). Interestingly, HIV-1 LTR contains binding 
Figure 12. Regulation of Blimp-1 Expression. 
Blimp-1 is induced via various mechanisms in different immune cells. 
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sites for both Bcl-6 and Blimp-1, suggesting that these factors directly regulate HIV-1 
transcription (Baron et al., 1997; Kaczmarek et al., 2013).
 
TFH cells support productive HIV-1 infection and are reported to expand during 
the course of HIV-1 infection (Lindqvist et al., 2012; Perreau et al., 2013). Bcl-6 is the 
master transcription factor for the generation of TFH cells (Yu et al., 2009). In particular, 
Bcl6 and Blimp-1 have an antagonistic relationship (Crotty et al., 2010; Martins and 
Calame, 2008). Unlike Bcl-6, Blimp-1 is highly expressed in TH2 cells compared to TH1 
cells and represses TH1 differentiation by repressing interferon, T-bet and Bcl-6 
expression (Cimmino et al., 2008).
 
 
 
6. Hypothesis 
 
Memory CD4
+
 T cells are the main cell reservoir harboring replication-
competent, yet transcriptionally quiescent HIV-1. Though HIV-1 latency is a rare event, 
primarily because the majority of HIV-1 proviruses are preferentially integrated in 
actively transcribed host genes, establishment of this replication competent but 
transcriptionally quiescent provirus does occur and is a significant barrier to a functional 
cure of HIV-1. Blimp-1 is a DNA-binding transcription factor that recruits multiple 
chromatin-modifying complexes, such as HDACs and methyltransferases, to targeted 
promoters. Blimp-1 is a key maturation factor of T cells and is upregulated in chronically 
HIV-1-infected patients. Together, these findings lead us to hypothesize that Blimp-1 
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binds to the HIV-1 LTR, inhibits HIV-1 transcription and contributes to HIV-1 latency 
(Fig. 13). A second hypothesis that is explored in this dissertation is that host promoters 
proximal to the HIV-1 LTR in the integrated provirus are active but have minimal impact 
on HIV-1 transcription.  
 
 
  
Figure 13. Model for Potential Role of Blimp-1 in HIV-1 Transcription. 
Blimp-1 and Bcl-6 have potential binding sites in HIV--1 LTR. I hypothesize that Blimp-
1, an antagonist of Bcl-6, contributes to paused RNAP II and thus to the establishment of 
HIV-1 latency. See text for details. 
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II.  Materials and Methods 
 
Cell Culture. Discarded deidentified tissues from otolaryngology surgeries performed at 
Boston Medical Center were mechanically separated and cultured on plastic plates for 2-3 
d to eliminate adherent cells. Cells in suspension were positively selected for CD4
+
 using 
the Dynabeads CD4 Positive Isolation Kit (Invitrogen). Peripheral blood mononuclear 
cells were isolated from whole blood by centrifuging through Histopaque gradient 
(Sigma-Aldrich). CD4
+
 T cells were positively selected using the Dynabeads CD4 
Positive Isolation Kit. Jurkat clone E6-1 was originally purchased from American Type 
Culture Collection (ATCC, Manassas, VA). Primary CD4
+
 T cells and Jurkat cells were 
propagated in RPMI 1640 supplemented with 10% fetal bovine serum (FBS), 100 
units/ml penicillin, 100 μg/ml streptomycin (P/S), and 0.2 M L-glutamine. Human 
embryonic kidney 293T cells (HEK293T) were purchased from ATCC and cultured in 
Dulbecco's modified Eagle's medium containing 10% FBS and P/S. Inducible Jurkat cell 
lines were a kind gift from Dr. Olaf Kutch and were previously described (Duverger et 
al., 2009). Cells were incubated in a 37 C humidified incubator with 5% CO2. Cells were 
either left untreated, or activated with 0.1 μg/ml anti-human CD3 (BD Biosciences) and 
1.0 μg/ml anti-human CD28 (BD Biosciences) for 30 min. 5 μg/ml of goat anti-mouse 
antibody (Sigma) was added to crosslink the receptors. T cells were harvested 24 h post-
stimulation. 
Polychromatic flow cytometry. CD4
+
 T cells were isolated from whole blood by 
negative selection using RosetteSep
TM
 Human CD4
+
 T Cell Enrichment Cocktail 
(STEMCELL Technologies). To sort T cell subsets cells were stained with CD3-
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PacificBlue (BD Biosciences), CCR7-PE-Cy7 (BioLegend), CD45RA-PE-Cy5.5 
(Invitrogen), CD27-PE (BD Biosciences), CD4-APC (BioLegend). T cell subsets were 
separated with FACSAria. 
Transfections, Virus Generation and Infections. HIV-1 LTR/GLS-luciferase reporter 
constructs with an intact or mutated (GAAAGCGAAAG mutated to GCCCGCGCCCG) 
ISRE or NL4-3ΔTat-luciferase, Blimp-1, Tat, RSV LTR-LUC (Yamamoto et al., 1980), 
FIP-LUC(Meiering et al., 2001) and DHFR-LUC (Gummuluru and Emerman, 1999) 
expression constructs were transiently transfected into HEK293T cells via calcium 
phosphate transfection as described previously (Natarajan et al., 2013). The RSV-LUC, 
FIP-LUC and DHFR-LUC were generously provided by Dr. S. Gummuluru, Boston 
University School of Medicine. Luciferase assays were performed 48 h post-transfection 
using Luciferase Assay System (Promega). 
Lentiviral vectors pNL4-3-Luc(+)Env(−)Nef(−) (Henderson et al., 1995) (obtained from 
NIH AIDS Research and Reference Reagent Program), Blimp-1 shRNA (Dharmacon), 
FUGW Blimp-1 (kindly provided by Dr. Kathryn Calame, Columbia University, New 
York), NELF shRNA (Dharmacon) were packaged by cotransfecting Tat, RSV-Rev, 
Gag/Pol and VSV-G into HEK293T cells using calcium phosphate as previously 
described (Natarajan et al., 2013). HIV-1 titers were determined using a p24 ELISA 
(PerkinElmer). Viruses were collected 48 h post-transfection and filtered through a 
Puradisc 25 Syringe Filter with 0.45-μm Polyethersulfone membrane (Whatman). Jurkat 
cells were infected by culturing with supernatants containing HIV-1-LUC or lentiviral 
constructs for 12–16 h. CD4+ T cells were activated with 2μg/mL PHA and 10ng/mL 
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PMA for 16 h, rested for 12 h and infected by culturing with HIV-1-containing 
supernatant or spinoculated with HIV-1-LUC supernatant plus 1 µg/ml polybrene for 1.5 
h at 1,200 ×g without prior activation described by O’Doherty et al (O'Doherty et al., 
2000). 
Quantitative RT-PCR. RNA was prepared by resuspending cells in TRIzol (Life 
Technologies), and cDNA was generated using SuperScript II Reverse Transcriptase 
(Invitrogen) and random primers (Promega). GoTaq qPCR Master Mix (Promega) was 
used for quantitative real-time PCR reaction. Blimp-1 transcripts (+2074 to +2372) were 
amplified using 5’-CAGCTCGCCCACCTGCAGAA-3’ and 5’-
GCCGCAGCGCAGTTCCCTTT-3’ primers. Initiated HIV-1 transcripts (+1 to +40) 
were amplified using 5′- GGGTCTCTCTGGTTAGA-3′ and 5′-
AGAGCTCCCAGGCTCA-3′ primers and elongated HIV-1 transcripts (+5396 to +5531) 
were amplified using 5′-GACTAGAGCCCTGGAAGCA-3′ and 5′-
GCTTCTTCCTGCCATAGGAG-3′ primers as described previously (Natarajan et al., 
2013). β-actin mRNA was amplified using a QuantiTect primer assay (Qiagen). PCR was 
carried out for 45 cycles, and the relative expression was calculated using the ΔΔCt 
method (Livak and Schmittgen, 2001), normalizing specific amplification of the 
transcripts of interest to the β-actin control for each specific sample. The product detected 
in the sh-Control was a calibrator, and the transcript levels in samples were calculated as 
fold changes in comparison to sh-Control. 
Immunoblot Analysis and Antibodies. Whole-cell lysates were prepared by washing 
cells with cold PBS and lysing them with buffer containing 10 mM Tris-Cl (pH 7.4), 150 
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mM NaCl, 1.0 mM EDTA (pH 8.0), 2.0 mM sodium vanadate, 10 mM sodium fluoride, 
10 mM sodium pyrophosphate, 1% Triton X-100, 1.0 mM phenylmethylsulfonyl fluoride, 
and protease inhibitor mixture III (Calbiochem). Protein was measured using the BSA 
assay (Pierce). Samples were heated for 5 min at 100 °C before loading onto a 10% SDS-
PAGE gel. Proteins were transferred to a polyvinylidene difluoride membrane (Millipore) 
by electroblotting. Antibodies used were as follows: anti-Blimp-1 serum (kindly provided 
by Dr. Kathryn Calame, Columbia University, New York), anti-β-actin (Sigma-Aldrich), 
anti-Tat (4138; NIH AIDS Research and Reference Reagent Program), anti-Sp1 
(Upstate), anti-IRF-1 (Santa Cruz Biotechnology), anti-IRF-8 (Santa Cruz 
Biotechnology), anti-RNAP II (Santa Cruz Biotechnology), anti-AcH3 (Upstate 
Biotechnology) and rabbit IgG (Upstate Biotechnology). 
ChIP-qPCR. Chromatin immunoprecpitations were performed as previously described 
(Natarajan et al., 2013). Quantitative real-time PCR analysis was carried out using SYBR 
green reagents and the primers 5′-GACTTTCCGCTGGGGACTTTC-3′ and 5′-
CTAACCAGAGAGACCCAGTAC-3′, which amplify the −102 to +16 region of HIV-1 
LTR, 5’-CTGGGAGCTCTCTGGCTAACTA-3’and 5’-
TTACCAGAGTCACACAACAGACG-3’, which amplify the +30 to +134 region of 
HIV-1, 5′-TCCCTCAGACCCTTTTAGTCAG-3′ and 5′- 
GTCGAGAGAGCTCCTCTGGTTT-3′, which amplify the +142 to +237 region of HIV-
1, and 5’-ACAGTACTGGATGTGGGTGATG-3’and 5'-
AATCCCTGGTGTCTCATTGTTT-3’, which amplify the +2415 to +2522 region of 
provirus. 
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Statistical analysis. Statistical analysis was carried out using Student t test. A two-tailed 
distribution was performed on paired samples. Values of <0.01 were considered 
significant. 
 
 
III.  Blimp-1 Represses HIV-1 Transcription in Memory CD4
+
 T Cells 
 
1.  Introduction 
 
 Blimp-1 is a key regulator of T cell differentiation and reciprocal inhibitor of Bcl-
6. Bcl-6 supports differentiation of TFH, a cell subset that supports robust HIV-1 
replication (Lindqvist et al., 2012; Perreau et al., 2013). In CD4
+
 T cells Blimp-1 
represses transcription of IL-2 gene (Martins et al., 2008) whose promoter share common 
cis-elements with HIV-1 LTR. Recent studies have shown that Blimp-1 is expressed at 
high levels in CD4
+
 T cells from HIV-1-infected patients and that it is induced in T cells 
by stimulation with HIV-1-pulsed DCs (Che et al., 2012; de Masson et al., 2014; Seddiki 
et al., 2013; Shankar et al., 2011). Therefore, it is important to decipher the role that 
Blimp-1 plays in HIV-1 infection  
In this chapter I show that Blimp-1 binds downstream of HIV-1 LTR to a region 
called ISRE and represses Tat-dependent and Tat-independent HIV-1 transcription. 
Blimp-1 favors closed chromatin structure at Nuc-1 by inhibiting its acetylation. Blimp-1 
contributes to the accumulation of short HIV-1 mRNA transcripts and decreases RNAP II 
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processivity. I also show that Blimp-1 contributes to the development and maintenance of 
HIV-1 latency in memory CD4
+
 T cells, the main reservoir of latent HIV-1.  
 
 
2.  Results 
 
2.1. Blimp-1 is Expressed in Primary Human CD4
+
 Cells Including Memory CD4
+
 T 
Cells.  
Although Blimp-1 expression has been characterized in murine T cells I wanted to 
confirm that it shared a similar expression pattern in human primary CD4
+
 T cells. CD4
+
 
T cells were isolated from tonsils, a rich source of follicular helper T cells (TFH), and 
from peripheral blood. Blimp-1 mRNA was detected by qRT-PCR and protein with 
immunoblots. Consistent with previous reports (Johnston et al., 2009) tonsillar CD4
+
 T 
cells expressed low levels of Blimp-1 compared to the CD4
+
 T cells isolated from whole 
blood (Fig. 14A). Activation with anti-CD3 and anti-CD28 antibodies resulted in 3-fold 
increase in Blimp-1 mRNA and protein levels (Fig. 14B and C). 
I also examined Blimp-1 expression in different memory CD4
+
 T cell populations 
obtained from peripheral blood. Flow cytometry based on CD45RA, CD27 and CCR7 
expression was used to enrich for naïve T cells (TN; CD4
+
CD3
+
CD45RA
+
), central 
memory T cells (TCM; CD4
+
CD3
+
CD45RA
-
CCR7
+
CD27
+
), transitional memory T cells 
(TTM; CD4
+
CD3
+
CD45RA
-
CCR7
-
CD27
+
) and effector memory T cells (TEM; 
CD4
+
CD3
+
CD45RA
-
CCR7
-
CD27
-
) (Fig. 14D). Although TCM have been implicated as 
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the primary cell type that is latently infected, recent reports suggest that TEM and TTM 
contribute to the latent HIV-1 reservoir (Bacchus et al., 2013; Chomont et al., 2009; 
Lassen et al., 2012). Blimp-1 mRNA was measured in memory cells by qRT-PCR and 
protein levels were determined by immunoblots. Blimp-1 expression was 10-fold higher 
in long-lived TCM compared to naïve T cells, whereas, even higher levels of Blimp-1 was 
observed in TTM and TEM (Fig. 14E, F). Overall, Blimp-1 is present in multiple T cell 
populations but is expressed at significantly higher levels in CD4
+
 T memory cells found 
within the latent reservoir.  
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2.2. Blimp-1 Binds to the ISRE Element Downstream of the 5’ HIV-1 LTR in 
Primary CD4
+
 Cells 
 
 Based on the transcriptional repressor function of Blimp-1 and my data showing 
its high expression in CD4
+
 memory T cells I hypothesized that Blimp-1 limits HIV-1 
expression in these cells. To determine if Blimp-1 regulates HIV-1 LTR activity I 
performed co-transfection experiments with Blimp-1 and an HIV-1 LTR reporter. Blimp-
1 inhibited HIV-1 LTR-driven luciferase reporter gene (HIV-1 LTR-LUC) by 67% when 
overexpressed in HEK293T cells (Fig. 15A). Overexpression of the HIV-1 transcriptional 
activator, Tat, was unable to rescue HIV-1 LTR-mediated transcription in the presence of 
Blimp-1 (Fig. 15A). In addition, Blimp-1 inhibited an HIV-1 clone that lacked Tat (ΔTat-
Figure 14. Blimp-1 is Expressed in CD4
+
 Memory T Cells. 
A) CD4
+
 cells were isolated from peripheral blood and tonsils and Blimp-1 was 
measured by qRT-PCR. B) Blimp-1 levels were measured by qRT-PCR in 
unstinmulated or CD3 + CD28 stimulated primary peripheral CD4
+
 T cells. β-actin 
was used as a reference gene to normalize values. C) Immnoblots of lysates from 
resting and CD3 + CD28 activated primary peripheral CD4
+
 T cells for Blimp-1, Sp1 
and -actin. Sp1, a transcription factor, and -acting served as loading controls.  D) 
Sorting strategy and staining profiles for T cell subsets. T cells were stained with 
Pacific Blue–labeled antibody to CD3, APC–labeled antibody to CD4, PE-Cy7–
labeled antibody to CCR7, PE-Cy5.5-labeled antibody to CD45RA and PE-labeled 
antibody to CD27. T cell subsets were separated by FACSAria into naïve T cells (TN; 
CD4
+
CD3
+
CD45RA
+
), central memory T cells (TCM; CD4
+
CD3
+
CD45RA
-
CCR7
+
CD27
+
), transitional memory T cells (TTM; CD4
+
CD3
+
CD45RA
-
CCR7
-
CD27
+
) 
and effector memory T cells (TEM; CD4
+
CD3
+
CD45RA
-
CCR7
-
CD27
-
). E) and F) 
Expression of Blimp-1 in sorted memory CD4
+
 T cell populations measured by E) 
qRT-PCR using β-actin as a reference gene and by F) immunoblots. These 
experiments represent CD4
+
 cells obtained from at least three healthy individuals. 
Bars show average values ±SD, n=3. *p < 0.05 and ***p < 0.001 (Student’s t test). 
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HIV-1-LUC) by only 30% but repressed transcription by greater than 70% when Tat was 
added back by co-transfection (Fig. 15B). Blimp-1 is not acting as a general repressor in 
these experiments since it failed to repress expression driven by Rous sarcoma virus LTR 
(RSV LTR) (Yamamoto et al., 1980) and foamy virus internal promoter (FIP) (Meiering 
et al., 2001) and even activated the dihydrofolate reductase (DHFR) (Gummuluru and 
Emerman, 1999) promoter (Fig. 15C). These data indicate that Blimp-1 inhibits Tat-
dependent HIV-1 transcription.  
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I explored whether Blimp-1 regulates HIV-1 expression in CD4
+
 T cells. I 
established a Jurkat T cell line that stably overexpressed Blimp-1 and infected it with a 
single cycle env-minus HIV-1-luciferase virus (HIV-1-LUC). HIV-1 transcription, as 
measured by the luciferase assay, was decreased by 55% in cells overexpressing Blimp-1 
(Fig. 15D). In addition, primary human CD4
+
 T cells were infected with a HIV-1-LUC 
virus (Henderson et al., 1995) and Blimp-1 was overexpressed using a lentiviral vector. 
Transduction of cells with Blimp-1 lentivirus resulted in over 13-fold increase in Blimp-1 
mRNA (Fig. 15E). Cells overexpressing Blimp-1 had 65% decrease in HIV-1 
transcription measured by HIV-1 mRNA levels (Fig. 15E) and over 90% inhibition of 
HIV-1 replication measured by HIV-1 p24 ELISA (Fig. 15E). The data from Jurkat T 
cells and primary human CD4
+
 T cells confirmed that Blimp-1 is a repressor of HIV-1 
transcription.  
Figure 15. Blimp-1 Represses Tat-dependent HIV-1 Transcription. 
A) and B) HEK293T cells were transfected with viral clones HIV--1 LTR-LUC 
containing the TAR element (A) or ΔTat-HIV-1-LUC (B) and vector control or 
Blimp-1 in the absence or presence of Tat. Luciferase assays and western blot 
analyses were performed 48 h post-transfection. (C) HEK293T cells were transfected 
with HIV--1 LTR-LUC, RSV LTR-LUC, FIP-LUC, DHFR-LUC and vector control 
or Blimp-1. Luciferase assays and western blot analyses were performed 48 h post-
transfection. (D) Jurkat T cells stably transduced with Blimp-1 lentivirus were 
infected with HIV-1. 48 h post-infection cells were lysed and luciferase activity was 
measured (E) 16 h post-HIV-1 infection primary CD4
+
 cells were transduced with 
empty lentiviral vector or with vector expressing Blimp-1. 72 h post-transduction 
expression of Blimp-1 and HIV-1 were measured by qRT-PCR. HIV-1 released into 
supernatants was assessed by measuring p24 by an ELISA. These experiments were 
performed in triplicates and the data represent at least three independent experiments. 
Experiments with primary cells were performed with cells from at least three different 
people. White bars indicate vector control; black bars indicate Blimp-1 lentiviral 
vector. Bars show average values ±SD, n=3. *p < 0.05 , **p < 0.01 and ***p < 0.001 
(Student’s t test). 
  
54 
HIV-1 provirus has four putative Blimp-1 binding sites, GAAAG, with two sites 
upstream of the transcription start site that overlap the NF-κB sites (-104 to – 80 bp) and 
a second set of sites located downstream of the transcriptional start site in an interferon 
sensitive response element (ISRE; +200 to +218 bp) (Liang et al., 1997) (Fig. 16A). Both 
regions have been reported to modulate HIV-1 transcription (Liang et al., 1997; Nabel 
and Baltimore, 1987). Mutating the HIV-1-ISRE ameliorated Blimp-1-mediated 
repression of HIV-1 following co-transfection into HEK293T cells (Fig. 16B). 
Furthermore, chromatin immunoprecipitations (ChIPs) demonstrate that Blimp-1 directly 
binds HIV-1 provirus. Chromatin was prepared from CD4
+
 T cells infected with HIV-1 
and protein-DNA complexes were enriched with Blimp-1-specific antibody. ChIPs show 
modest Blimp-1 binding at the -104/-80 bp site and 9-fold higher Blimp-1 binding at the 
+200/+218 bp ISRE site (Fig. 16C). Following T cell activation, Blimp-1 binding was 
not detected at the HIV-1 ISRE element despite increases in Blimp-1 mRNA and protein 
(Fig. 16C, Fig. 14B and C). Blimp-1 did not exclude binding of interferon regulatory 
factors (IRFs) IRF-1 and IRF-8 to the HIV-1 ISRE (Fig. 16D). These results suggest that 
Blimp-1 represses HIV-1 transcription by directly binding the proviral ISRE element. 
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The above gain of function experiments demonstrated that Blimp-1 represses 
HIV-1 expression. To determine if Blimp-1 limits HIV-1 expression in the context of 
primary cells I reduced Blimp-1 expression in primary CD4
+
 T cells using shRNA. I 
infected CD4
+
 T cells with HIV-1-LUC, transduced the infected cells with sh-Blimp-1 
lentivirus and monitored HIV-1 expression. The efficacy of Blimp-1 knock-down was 
confirmed 96 h post-transduction by qRT-PCR (Fig. 17A) and immunoblots (Fig. 17B). 
Diminishing Blimp-1 increased basal HIV-1 transcription and replication as measured by 
qRT-PCR (Fig. 17C), luciferase assay (Fig. 17D) and p24 ELISA (Fig. 17E) indicating 
that Blimp-1 limits HIV-1 transcription in primary CD4
+
 T cells. Activating T cells 
through CD3+CD28 following Blimp-1 knockdown did not further induce HIV-1 
transcription and actually decreased HIV-1 transcription by 80% suggesting that Blimp-1 
was required for optimal induction of HIV-1 transcription (Fig. 17C). These data indicate 
that Blimp-1 acts as both a repressor and transcriptional activator in the context of HIV-
1-infected primary T cells. However, the ability of Blimp-1 to activate HIV-1 
Figure 16. Blimp-1 Binds HIV-1 Provirus. 
(A) The location of HIV--1 LTR, four putative Blimp-1-binding sites and ISRE 
mutations in provirus. (B) HEK293T cells were transfected with HIV--1 LTR-LUC or 
mISRE-HIV--1 LTR-LUC and control vector or Blimp-1 in the absence or presence of 
Tat.  Luciferase assays and western blot analyses were performed 48 h post-
transfection. (C, D) 96 h post-HIV-1 infection primary human CD4
+
 cells were 
activated with anti-CD3 and anti-CD28 antibodies for 24 h and ChIPs were performed 
using anti-Blimp-1, anti-IRF-1, anti-IRF-8 or anti-rabbit antibody. Binding was 
detected with -102F/+16R and +142F/+237R HIV-1 primer sets. These data are 
performed in triplicate and represent at three independent experiments. Bars show 
average values ±SD, n=3. *p < 0.05, **p < 0.01 and ***p < 0.001 (Student’s t test). 
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transcription is independent of Blimp-1 binding to provirus since ChIPs show it is 
displaced following T cell activation (Fig. 17C). 
To gain insight into how Blimp-1 limits HIV-1 transcription I examined with 
ChIPs the distribution of RNA Polymerase II (RNAP II) on the HIV-1 genome. In cells 
expressing Blimp-1 there was an accumulation of RNAP II at the transcriptional start site 
and modest amounts of RNAP II downstream suggesting that Blimp-1 leads to RNAP II 
promoter proximal pausing (Fig. 17F). Diminishing Blimp-1 reduced RNAP II at the 
promoter and increased RNAP II downstream in the provirus by 3-fold consistent with 
RNAP II release and greater processivity (Fig. 17F). I also used qRT-PCR to measure 
initiated versus elongated transcripts. In control cells there was an accumulation of 
initiated short HIV-1 mRNA but low expression of full length mRNA (Fig. 17G) as 
would be expected with RNAP II pausing (Zhang et al., 2007). Decreasing Blimp-1 with 
shRNA altered the ratio of initiated to elongated HIV-1 mRNA so that the ratio was 
approximately one indicating processive transcriptional elongation (Fig 17G). 
Furthermore, knocking down Blimp-1 led to an increase in histone H3-acetylation 
(AcH3) at the positioned nucleosome (nuc-1) (Fig. 17H). These data suggest that Blimp-
1 targets multiple steps of transcription regulation to limit HIV-1 transcriptional 
elongation. 
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Blimp-1 was most highly expressed in memory CD4
+
 T cells which do not 
support efficient HIV-1 transcription. To examine whether Blimp-1 was limiting HIV-1 
transcription in these cells I infected isolated memory CD4
+
 T cells with HIV-1 by 
spinoculation (O'Doherty et al., 2000) which has been shown to facilitate infection of 
cells without using mediators that activate T cells and then decreased Blimp-1 with sh-
Blimp-1 lentivirus. Spinoculation enhances viral binding which increases infection of 
cells without activating stimuli and results in higher integration rates than infection of 
cells in the absence of spinoculation. Decreasing Blimp-1 levels in all three CD4
+
 T cell 
Figure 17. Blimp-1 Represses HIV-1 Transcription in Resting CD4
+
 T Cells. 
HIV-1-infected primary CD4
+
 cells were transduced with sh-Ctrl and sh-Blimp-1. 72 
h post-knockdown cells were activated with anti-CD3 and anti-CD28 antibodies for 
24 h. Expression of Blimp-1 was measure by A) qRT-PCR and B) immunoblots. HIV-
1 expression was assayed by qRT-PCR using primers for (C) elongated HIV-1 mRNA 
and (G) initiated short transcripts, D) luciferase assay and E) HIV-1 p24 ELISA. ChIP 
analysis used anti-rabbit and anti-RNAP II (F) oranti-AcH3 (H) antibody and 
+30F/+134R and +2415F/+2522R HIV-1 primer sets. These experiments were 
performed in triplicate and the data are representative of at least three independent 
experiments. White bars indicate sh-control; black bars indicate sh-Blimp-1. Bars 
show average values ±SD, n=3. *p < 0.05, **p < 0.01 and ***p < 0.001 (Student’s t 
test). 
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memory populations resulted in significant increases, 2 to 12-fold, in HIV-1 transcription 
(Fig. 18B). The levels of induction correlated with the efficiency of Blimp-1 knockdowns 
observed with more modest induction in TCM and TEM cells in which Blimp-1 
knockdowns were inefficient compared to robust induction in TTM where Blimp-1 
expression was decreased by greater than 80% (Fig. 18A). These findings support a 
model in which Blimp-1 expression correlates with limited basal HIV-1 transcription in T 
memory cells.  
 
Figure 18. Blimp-1 Represses Basal HIV-1 Transcription in Primary Memory 
CD4
+
 T Cells. 
TCM, TTM and TEM sorted as described above were infected with NL4-3 HIV-1 by 
spinoculation. 16 h post infection cells were transduced with sh-Ctrl and sh-Blimp-1. 
72 h post-knockdown mRNA was collected. Expression of (A) Blimp-1 and (B) HIV-
1 was measured by qRT-PCR using β-actin as a reference gene. These experiments 
were performed in triplicate and are representative of three separate infections from T 
cells obtained from three patients. Bars show average values ±SD, n=3.  *p < 0.05, 
**p < 0.01 and ***p < 0.001 (Student’s t test). 
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2.3. T Cell Activation and Treatment with G9a and HDACs Inhibitors Do Not 
Abolish Blimp-1-Mediated HIV-1 Repression in Jurkat Cells 
 
Posttranslational modifications of histones have been shown to regulate 
transcription of HIV-1. Trichostatin A (TSA), an inhibitor of class I and II HDACs, has 
been shown to increase HIV-1 transcription by favoring open chromatin structure (Van 
Lint et al., 1996). BIX01294, an inhibitor of the methyltransferase G9a, was also 
demonstrated to increase HIV-1 transcription and to reactivate latent HIV-1 (Imai et al., 
2010). To gain insight into the mechanism by which Blimp-1 halts HIV-1 transcription I 
have treated HIV-1-infected Jurkat cells stably overexpressing Blimp-1 with TSA and 
BIX01294 and activated them with anti-CD3+28 Abs in the presence of the inhibitors. 
TSA induced HIV-1 transcription, however Blimp-1 was still able to repress it (Fig. 19). 
Treatment with BIX01294 did not induce HIV-1 transcription and Blimp-1 was able to 
repress HIV-1 transcription in not activated cells at the highest concentration (Fig. 19). In 
contrast to primary CD4
+
 cells, the CD3+28 activation of Jurkat cell lines did not abolish 
Blimp-1 mediated repression of HIV-1 transcription highlighting the differences between 
the two cell types (Fig. 19). These results suggest that Blimp-1-mediated repression of 
HIV-1 transcription does not depend on HDACs and G9a. However, these experiments 
lack the appropriate controls and should be repeated in primary CD4
+
 T cells in which 
Blimp-1 affects HIV-1 transcription in different manner than in Jurkat cell lines upon T 
cell activation. 
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Figure 19. G9a and HDACs Inhibitors do not Inhibit Blimp-1-mediate 
Repression of HIV-1 Transcription. 
Jurkat T cells stably over-expressing Blimp-1 were infected with HIV-1 LUC. 12 h 
post infection cells were pre-treated with different concentrations of TSA, BIX01294 
or DMSO for 1 h. Cells were activated with anti-CD3+28 antibodies in the presence 
of inhibitors for 16 h.  Cells were lysed and luciferase activity was measured. Bars 
show average values ±SD, n=3.  *p < 0.05 and ***p < 0.001 (Student’s t test). 
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3.  Conclusions and Discussion 
 
Memory CD4
+
 T cells are a major reservoir of latent HIV-1 and their longevity 
and homeostatic proliferation prevents virus clearance and supports HIV-1 persistence. 
Although several mechanisms potentially inhibit HIV-1 transcription, T cell specific 
transcription factors that intrinsically program the maturation of CD4
+
 memory T cells 
could contribute to the propensity of HIV-1 to become repressed in these cells. I present 
evidence that the lymphoid differentiation factor Blimp-1 limits HIV-1 transcription in 
CD4
+
 memory T cell subsets. 
Blimp-1 is expressed in a range of immune cells, such as B cells, macrophages, 
dendritic cells and T cells. I confirmed that Blimp-1 is differentially expressed in CD4
+
 T 
cells, with low levels in TN and CD4
+
 tonsillar cells but elevated expression in cells that 
have been shown to contribute to the latent reservoir, TCM, TTM and TEM. I also showed 
that Blimp-1 is induced upon T cell activation. Blimp-1 in part influences T cell 
maturation and function by regulating the expression of key lineage restricting 
transcription factors including PAX5, STAT6, Bcl-6 and T-bet (Cimmino et al., 2008; 
Lin et al., 2002; Shaffer et al., 2002). Furthermore, Blimp-1 is required for robust CD4 
and CD8 T cells antiviral responses against influenza and lymphocytic choriomeningitis 
virus (LCMV) and mediates murine gamma herpesvirus latency in splenocytes (Hua et 
al., 2013; Kallies et al., 2009; Rutishauser et al., 2009; Shin et al., 2009; Siegel et al., 
2010). Blimp-1 is associated with increased expression of inhibitory receptors and 
decreased polyfunctionality of exhausted CD4
+
 T cells during LCMV infection 
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(Crawford et al., 2014). In TH1 Blimp-1induces the expression of IL-10, a cytokine that 
suppresses anti-viral T cell responses, while in CD8
+ 
T cells Blimp-1-mediated repression 
of CD25 and CD27 decreases their survival and differentiation into memory cells during 
LCMV infection (Parish et al., 2014; Shin et al., 2013). During Toxoplasma gondii 
infection Blimp-1 suppresses inflammation which increases survival rate (Neumann et 
al., 2014). In chronically infected HIV-1 patients Blimp-1 is elevated in CD4
+
 T cells and 
correlates with an increase in T cell exhaustion markers (de Masson et al., 2014; Seddiki 
et al., 2013). This increase in Blimp-1 may be a direct result of infection since HIV-1-
pulsed dendritic cells enhance Blimp-1 expression (Che et al., 2012; Shankar et al., 
2011). My results demonstrate that Blimp-1 limits HIV-1 transcription in T memory cells 
consistent with its function as a transcriptional repressor in different T cell subsets. 
Blimp-1 is expressed in macrophages and dendritic cells and it may limit HIV expression 
and promote latency in them although this possibility has not been explored. 
Blimp-1 binds a GAAAG consensus sequence which is also found in ISREs 
present in Blimp-1 regulated genes CIITA, IDO1 and IFN-λ1 (Barnes et al., 2009; 
Piskurich et al., 2000; Siegel et al., 2011b). Although HIV-1 provirus contains four 
putative Blimp-1-binding sequences (Kaczmarek et al., 2013), I detected Blimp-1 binding 
only at the HIV-1 ISRE element. This cis-element has been implicated in regulating HIV-
1 transcription by recruiting IRF family proteins IRF-1 and IRF-8 (Sgarbanti et al., 2002). 
Blimp-1 binds this element in resting cells and is displaced following T cell activation. It 
is possible that Blimp-1 antagonizes or competes with the transcriptional activator IRF-1, 
although, I do not observe significant changes in IRF-1 or IRF-8 binding in the absence 
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or presence of Blimp-1 or in response to T cell activation. There is also a possibility that 
T cell activation results in post-translational modifications of Blimp-1, such as 
sumoylation, phosphorylation or ubiquitination. 
Blimp-1 mediates repression of genes by recruiting epigenetic factors such as 
methyltransferases G9a, Prmt5 and LDS1, Groucho-proteins and histone deacetylases to 
promoters (Ancelin et al., 2006; Gyory et al., 2004; Ren et al., 1999; Su et al., 2009; Yu 
et al., 2000). LSD-1 and G9a limit HIV-1 transcription and are candidates for the 
repression observed in CD4
+
 memory T cells (Imai et al., 2010; Le Douce et al., 2012). I 
observed that decreasing Blimp-1 increases acetylation at nuc-1 and releases RNAP II 
pausing. Blimp-1 limiting transcription elongation is also consistent with the observation 
that Tat cannot rescue HIV-1 expression in the presence of Blimp-1 and suggests that it is 
targeting a step prior to transcription elongation and recruitment of P-TEFb which is 
mediated by Tat.  
Blimp-1 can act as a transcriptional activator and is necessary for the induction of 
IL-10 and XBP-1 (Cretney et al., 2011; Iwasaki et al., 2013; Lin et al., 2002). I also 
observe that Blimp-1 can act as a repressor and trans-activator in co-transfections with 
select promoters and in primary CD4
+
 T cells. Intriguingly, Blimp-1 is required for 
efficient induction of HIV-1 transcription upon T cell activation. However, Blimp-1 does 
not occupy either set of binding sites following T cell activation despite increased Blimp-
1 expression following CD3 + CD28 activation suggesting that Blimp-1 is not directly 
inducing HIV-1 transcription. The mechanism by which Blimp-1 induces HIV-1 
transcription following activation is not clear and may reflect Blimp-1 interacting with 
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other transcription factors, or its ability to influence the expression of other host genes, 
cytokines and restriction factors that regulate HIV-1 transcription. Another transcription 
factor that functions in a similar manner is DSIF. Unphosphorylated DSIF functions as a 
transcriptional repressor promoting RNAP II pausing at promoters (Yamaguchi et al., 
2002). Phosphorylation of DSIF by P-TEFb changes it to a transcriptional activator 
(Peterlin and Price, 2006). 
I propose a model in which Blimp-1 is highly expressed in memory CD4
+
 T cells 
which do not support robust HIV-1 replication. In resting cells Blimp-1 binds the HIV-1 
ISRE and represses HIV-1 transcription elongation whereas upon T cell activation 
Blimp-1 is released from HIV-1 provirus derepressing proviral transcription (Fig. 20). I 
show that Blimp-1 is a transcriptional repressor of HIV-1 and its expression in memory 
CD4
+
 T cells makes them prone to HIV-1 latency. Understanding how Blimp-1 is 
regulated and the transcriptional processes it coordinates to silence HIV-1 expression will 
provide insights into the establishment and maintenance of the HIV-1 reservoir. 
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Figure 20. Model for the Role of Blimp-1 in HIV-1 Transcription. 
Blimp-1 is highly expressed in memory CD4
+
 T cells, binds the HIV-1 ISRE and 
inhibits Tat-dependent HIV-1 transcription. Following T cell activation Blimp-1 is 
released from HIV-1 provirus which correlates with increased RNAP II processivity, 
histone H3 acetylation and enhanced HIV-1 transcription. 
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IV.  Neighboring Promoters and Their Influence on HIV-1 Transcription 
 
1.  Introduction 
 
HIV-1 latency is regulated by binding of factors to HIV-1 LTR, chromatin 
structure, intrinsic T cell factors, as well as NELF-mediated stalling of RNAP II at the 
viral promoter. Transcription from host neighboring genes in which HIV-1 is integrated 
has been suggested to influence HIV-1 transcription and establishment of latency. 
However, although HIV-1 has been shown to integrate into transcriptionally active host 
genes, proviral latency is established. Therefore, I hypothesized that active host genes 
have minimal impact on HIV-1 transcription. To investigate the role of proximal host 
promoters on HIV-1 transcription I have used five different cell lines with inducible 
expression of HIV-1; one with parallel promoters, three with convergent promoters and 
one with provirus integrated between two host genes (Fig. 21). My results demonstrate 
that these cells are differentially responsive to reactivation induced by T cell activation. 
Four out of five inducible cell lines were minimally responsive to treatment with HDAC 
inhibitor indicating that chromatin remodeling agents are not a general mechanism of 
repression. Additionally, I show that transcription of host genes does not exclude 
transcription from a proximally integrated HIV-1 LTR, and that HIV-1 integration may 
lead to an increase in transcription of the neighboring host gene. The majority of the cells 
had accumulation of short HIV-1 mRNA transcripts and bound RNAP II and NELF at the 
repressed HIV-1 LTR. Decreasing NELF levels led to reactivation of provirus suggesting 
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that NELF-mediated RNAP II pausing is a general mechanism of proviral repression in 
these cells. 
 
 
2.  Results 
 
2.1. Characterization of Inducible Cell Lines 
 
The inducible Jurkat cell lines, CA5, BA1, 11B10, EF7 and CG3 were a kind gift 
from Dr. Olaf Kutsch and the mapping of integration and orientation of HIV-1 provirus 
in these cells was performed by Dr. Frank Wolschendorf. The inducible cell lines were 
generated by infecting Jurkat T cells with HIV-1-GFP, activating GFP-non-expressors 
with PMA+PHA and establishing clonal cell lines from cells in which PMA+PHA 
treatment induced GFP expression (Duverger et al., 2009).CA5 cells have provirus 
integrated in the exon of RNA binding motif protein 12 (RBM12) in a parallel orientation 
(Fig. 21). RBM12 has been implicated in meibomian cell carcinoma (Kumar et al., 2007). 
RBM12 shares promoter and 5’exons with copine I (CPNE1) (Yang et al., 2008a). The 
function of RBM12 remains unidentified, while CPNE1 plays role in cell-cycle and 
proliferation (Skawran et al., 2008). BA1 cells have HIV-1 integrated in the intron of 
PDZ domain containing 8 (PDZD8) in a convergent orientation (Fig. 21). PDZD8 is a 
cytoskeleton-regulating protein that binds HIV-1 Gag and stabilizes HIV-1 capsid 
contributing to enhanced reverse transcription (Guth and Sodroski, 2014; Henning et al., 
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2010). PDZD8 is also a suppressor of Herpes Simplex Virus type-1 (HSV-1) replication 
(Henning et al., 2011). 11B10 cell line has HIV-1 inserted in the intron of HELZ in a 
convergent orientation (Fig. 21). HELZ is a zinc-finger containing RNA-helicase 
important for global translational initiation (Hasgall et al., 2011). HELZ interacts with 
RNAP II and histone methyltransferases, Smyd2 and Smyd3 (Diehl et al., 2010; 
Hamamoto et al., 2004). In EF7 cells HIV-1 is integrated in the intron of WHSC1 in a 
convergent orientation (Fig. 21). Wolf–Hirschhorn syndrome candidate 1 (WHSC1), also 
known as Multiple Myeloma SET domain (MMSET), is a histone H3 lysine 36 (H3K36) 
trimethyltransferase which together with the histone chaperone HIRA is implicated in 
incorporation of histone H3.3 into actively transcribed genes and which is required for 
IFN-induced transcription (Sarai et al., 2013). WHSC1 also interacts with Brd4 and P-
TEFb facilitating transcriptional elongation (Sarai et al., 2013). In CG3 cell line provirus 
is integrated between two genes, tigger transposable element derived 5 (TIGD5) and 
PYCRL, with a parallel orientation to TIGD5 and a convergent orientation to PYCRL 
(Fig. 21). TIGD5 is a member of the tigger subfamily of the pogo superfamily of DNA-
mediated transposons. PYCRL is cytosolic pyrroline-5-carboxylate reductase that 
catalyzes the reduction of ornithine to proline (De Ingeniis et al., 2012). 
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Figure 21. Proviral Integration Sites in CA5, BA1, 11B10, EF7 and CG3. 
Schematic of HIV-1 provirus integration sites relative to neighboring host promoter for 
latently infected Jurkat cells (obtained from the Kutsh lab UAB). 
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2.2. Repressed HIV-1 is Differentially Inducible 
 
Signals that activate T cells, such as signaling downstream of the CD3 and CD28 
receptors as well as treatment with Phorbol 12-myristate 13-acetate (PMA), a phorbol 
ester and phytohemagglutinin (PHA), a plant lectin present in red kidney beans, lead to 
induction of HIV-1 transcription and effective replication (Peterlin and Price, 2006). 
Activation with PHA requires intact CD3/TCR and increases intracellular free Ca
2++
 
(Weiss and Imboden, 1987) whereas PMA binds to and activates PKC (Manger et al., 
1987). To see if cells harboring repressed proviruses with divergent integration sites are 
responding in the same manner to T cell activation stimuli, CA5, BA1, 11B10, EF7 and 
CG3 cell lines were treated with PMA+PHA. Results indicate that provirus induction 
levels in response to PMA+PHA treatment range from 90-30% among T cell lines with 
the CA5 cells being the most inducible and the CG3 cells (harboring intragenic HIV-1 
provirus) being the least inducible (Fig. 22 A).  
HDACs have been shown to contribute to the repression of HIV-1 transcription 
by removing acetyl groups from histones, making the chromatin more condensed (Keedy 
et al., 2009). To explore the contribution of chromatin structure in limiting HIV-1 
expression I have treated cells with Trichostatin A (TSA), an inhibitor of the class I and 
II HDACs, which has been shown to be a potent inducer of HIV-1 transcription. The 
treatment with TSA was not as effective as treatment with PMA+ PHA at reactivating 
latent provirus (Fig. 22 B). TSA induced most HIV-1 expression in 11B10 and EF7 cells 
in which HIV-1 provirus and the host genes have convergent orientation (Fig. 22 B). 
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However, BA1 cells, which have both the host promoter and the HIV-1 LTR in the same 
orientation were minimally responsive to the TSA treatment (Fig. 22 B), implying that 
chromatin structure does not contribute to HIV-1 latency in all cell lines and that the 
promoter orientation does not impose a specific mode of transcriptional regulation of 
HIV-1 provirus. My data indicate that class I and II HDACs are not general regulators of 
HIV-1 transcription in these cell lines. This is consistent with the hypothesis that 
neighboring host genes being active and having open chromatin structure can influence 
transcription from the proximal HIV-1 LTR. 
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Figure 22. Provirus Integration Site Affects Reactivation Rate of Latent HIV-1. 
Cells were treated with 2μg/mL PHA and 10ng/mL PMA or 0.5μM TSA for 24 h. 
GFP expression was measured by flow cytometry. Data represent fold induction over 
background HIV-1-GFP expression. 
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2.3. Correlation between the Expression of Host Genes and HIV-1 Induction 
 
Because HIV-1 preferentially integrates into active host genes one may expect 
that HIV-1 transcription would interfere with transcription of the host gene (Lenasi et al., 
2008). Thus, the reactivation of HIV-1 would be at the expense of the host, leading to a 
decreased expression of the endogenous gene. However, treatment with PMA+PHA 
resulted in decreased host gene expression only in 11B10 and CG3 (PYCRL gene) (Fig. 
23). The m-RNA levels of the majority of neighboring host genes increased (BA1, EF7, 
CG3 (TIGD5 gene)) or remained constant (CA5 cells) upon T cell activation with 
PMA+PHA (Fig. 23). In addition, the integration of HIV-1 led to an increase in host gene 
expression in BA1, 11B10, EF7 and CG3 (TIGD5 gene). It is possible that host gene 
activity is crucial for the reactivation of provirus. These data indicated that host gene 
expression does not necessarily exclude HIV-1 expression. 
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2.4. RNAP II Pausing as Common Mechanism of HIV-1 Latency 
 
To determine if HIV-1 transcription in the inducible Jurkat cell line is inhibited at 
the step of transcriptional initiation or elongation I looked at the accumulation of short 
HIV-1 mRNA transcripts. Using qRT-PCR I have calculated the ratio of initiated to 
elongated HIV-1 mRNAs (Fig. 24). The ratio of initiated to elongated HIV-1 mRNA 
transcripts decreased upon PMA+PHA treatment in CA5, BA1 and 11B10 cells, 
indicating productive RNAP II transcription. CG3 cells also had accumulated short HIV-
1 transcripts, but to a much smaller degree (Fig. 24). However, EF7 cells did not contain 
accumulated initiated HIV-1 mRNAs (Fig. 24). The accumulation of short HIV-1 
mRNAs is consistent with the paused RNAP II at HIV-1 LTR which decreases upon T 
cell activation. Effective HIV-1 transcription is initiated and elongated HIV-1 mRNA is 
produced shifting the ration of initiated to elongated transcripts to “1”.  
 
Figure 23. Activation of Latent Cells Results in Altered Host Gene Expression.  
Uninfected Jurkat T cells as well as CA5, BA1, 11B10, EF7 and CG3 cells were treated 
with 2μg/mL PHA and 10ng/mL PMA for 24 h. Expression of the neighboring host gene 
mRNA was measured by qRT-PCR and normalized to β-actin.  
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RNAP II pausing is characterized by accumulation of RNAP II and NELF at the 
transcriptionally repressed promoter. The RNAP II promoter proximal pausing induced 
by NELF was confirmed in ChIP experiments looking at the binding of RNAP II and 
NELF to HIV-1 LTR. Using a ChIP assay, I detected high binding of RNAP II at HIV-1 
LTR in uninduced cells and this binding decreased upon activation with PMA+PHA 
representing release of a paused RNAP II (Fig. 25). Upon T cell activation, the levels of 
NELF, an inducer of RNAP II pausing at HIV-1 LTR, also decreased at the viral 
promoter (Fig. 25). These data suggest that HIV-1 induction correlates with a decrease in 
RNAP II pausing at HIV-1 LTR.  
Figure 24. RNAP II Pausing Occurs in Latent Cell Lines.  
Latently HIV-1-infected Jurkat cell lines were treated with 2μg/mL PHA and 10ng/mL 
PMA for 24 h. Expression of initiated and elongated HIV-1 was measured by qRT-PCR. 
These data are performed in triplicate and represent at three independent experiments. 
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Our laboratory identified the negative elongation factor (NELF) as a key player in 
mediating RNAP II promoter proximal pausing and repressing HIV-1 transcription 93 
(Natarajan et al., 2013). Data obtained by Dr. Malini Natarajan and Dr. Gillian Schiralli 
Lester indicate that knockdown of NELF in these inducible Jurkat cell lines reactivates 
provirus, although to varying degree (Fig. 26). Thus, HIV-1 provirus in the inducible cell 
lines is repressed by NELF-induced RNAP II pausing, a widespread mechanism of gene 
regulation (Gaertner et al., 2012; Rahl et al., 2010), which I propose as a general 
mechanism of HIV-1 repression and latency. 
Figure 25. T Cell Activation Results in Altered Recruitment of RNAP II. 
Cells were treated with 2μg/mL PHA and 10ng/mL PMA for 24 h. ChIP assays were 
performed to examine RNAP II and NELF binding to HIV--1 LTR. 
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3.  Conclusions and Discussion  
 
I explored the effect of neighboring host promoters on HIV-1 expression in 
different inducible Jurkat cell lines. Previous reports showed that transcription from the 
proximal host promoters may lead to repression of HIV-1 transcription. However, my 
data demonstrate that genes in the vicinity of the HIV-1 provirus and chromatin structure 
have minimal impact on the maintenance of HIV-1 latency in the inducible Jurkat cells. 
The fact that CG3 cells, which harbor intergenic provirus, are the least inducible suggests 
that HIV-1 integration into transcriptionally active genes helps reactivate HIV-1. Thus 
Figure 26. NELF Limits HIV-1 Transcription in Inducible Cells.  
Cell lines were transduced with shPRS Vector or shNelf-B specific lentivirus, 72 h post-
transduction GFP expression was measured by flow cytometry. The fold induction of 
GFP expression over the shPRS Vector sample is graphed for the representative 
experiment. 
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integration of the HIV-1 provirus into transcriptionally active genes instead of non-
coding DNA may actually help in its reactivation by assisting with promoter clearance of 
repressive factors or open chromatin. In fact, HIV-1 integration increased expression of 
the neighboring host gene by an unknown mechanism. It is possible that HIV-1 induces 
transcription of the host gene by disrupting repressive chromatin structure, obstructing 
binding of transcriptional repressors to the host gene or recruiting them away from the 
host neighboring promoter to HIV-1 LTR. The high transcriptional activity of host 
neighboring promoter was decreased upon HIV-1 induction only in 11B10 cells, 
implying that in this particular cell line high transcriptional activity of the host gene may 
lead to repression of HIV-1 LTR. It remains to be determined if the decrease in the HELZ 
gene expression in 11B10 is a result of interruption of transcriptional initiation or 
elongation of this gene. 
Recently RNAP II pausing has been shown to be one of the mechanisms of 
transcriptional interference (Palmer et al., 2009). My data show that all the inducible cell 
lines have high levels of RNAP II at HIV-1 LTR, as well as accumulation of short HIV-1 
mRNA transcripts, implying that proviruses are inhibited at the step of transcriptional 
elongation rather than initiation. The data showing HIV-1 induction upon NELF knock-
down are supportive of RNAP II promoter proximal.as the primary mechanism of HIV-1 
transcriptional repression. 
Upon cell activation, BA1, EF7 and 11B10 have differential expression of the 
neighboring host gene despite having HIV-1 integrated in convergent orientation. HIV-1 
induction decreased HELZ levels, did not affect PDZD8 expression, while it induced 
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WHSC1 levels. These differences may be possibly explained by the different distances of 
HIV-1 LTR from the proximal host gene promoter as well as the host gene promoter 
strength. In 11B10 cells, provirus is integrated 96,217 bp of HELZ compared to 36,311 
bp of PDZD8 in BA1 cells and 1,129 bp of WHSC1 in EF7 cells. These data suggest that 
the inhibition of neighboring host gene expression correlates positively with the distance 
between the host gene and viral promoter. One can also assume that the promoter of 
HELZ is weaker, while the promoters of WHSC1 and PDZD8 have the same or greater 
strength than HIV-1 LTR. 
My data demonstrate that T cell activation, inhibition of HDACs, as well as 
NELF-mediated RNAP II pausing play a differential role in maintaining the repression of 
provirus in inducible Jurkat cell lines. My data also suggests that although HIV-1 
insertion and induction differentially affect neighboring host genes, the expression of a 
host gene does not necessarily prevent the reactivation of the HIV-1 provirus. I propose a 
model in which HIV-1 transcription is repressed by a combination of mechanisms rather 
than by a single one. In this model NELF causes RNAP II pausing at HIV-1 LTR 
characterized by accumulation of short viral transcripts, while the closed chromatin 
structure at Nuc-1 may additionally prevent RNAP II from processing downstream 
provirus after its release from the pause. T cell activation leads to recruitment of 
transcriptional activators to HIV-1 LTR as well as the displacement of transcriptional 
repressors, such as Blimp-1, from provirus allowing efficient HIV-1 transcription. 
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V.  Conclusions 
 
The inability to target and eliminate latently infected memory CD4
+
 T cells 
remains a barrier to eradicating HIV-1 infection. In an effort to cure HIV-1 infection, 
strategies to purge transcriptionally repressed HIV-1 provirus from latent reservoirs have 
been employed to complement current antiretroviral therapies (Margolis and Hazuda, 
2013). Recent therapeutic approaches have focused on overcoming the repressive effects 
of chromatin, which has been implicated as a key regulator of HIV-1 transcription 
(Richman et al., 2009; Siliciano and Greene, 2011). For example, clinical trials have used 
HDAC inhibitors valproic acid (Archin et al., 2010; Routy et al., 2012) and vorinostat 
(Archin et al., 2012), which, despite modest ability to induce HIV-1 transcription in 
peripheral blood of HAART patients, did not decrease the HIV-1 reservoir. The limited 
success of these initial trials probably reflect the complexity of the latent reservoir in 
regards to the cells that are included in this compartment as well as the multiple 
mechanisms that establish and maintain latency (Richman et al., 2009; Schiralli Lester 
and Henderson, 2012; Siliciano and Greene, 2011). An additional confounder is that 
many of the factors that limit HIV-1 transcription are general transcriptional regulators 
which are necessary for normal gene expression. Targeting RNAP II, P-TEFb, and 
chromatin remodeling factors will likely be toxic, lack specificity, and have an impact on 
global gene expression.  
I wanted to gain insight into the mechanisms that might contribute to HIV-1 
latency in the context of T cells. My work explored two possible mechanisms of HIV-1 
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latency: tissue specific factors and host neighboring promoters. I show that Blimp-1 is an 
important transcriptional repressor of HIV-1 in memory CD4
+
 T cells and that 
neighboring genes have minimal impact on HIV-1 transcription. I also demonstrate that 
RNAP II pausing appears to be necessary for establishment of proviral latency in both 
scenarios. 
 
Blimp-1-mediated repression of HIV-1 transcription in memory CD4
+
 T cells 
CD4
+
 T cell subsets differentially support HIV-1 replication. For example, 
quiescent CD4
+
 memory T cells are susceptible to HIV-1 infection but do not support 
robust HIV-1 transcription and have been implicated as the primary reservoir of latent 
HIV-1. T cell transcription factors that regulate maturation potentially limit HIV-1 
transcription and mediate the establishment and maintenance of HIV-1 latency. Attempts 
to purge HIV-1 from the latent reservoir by targeting general biochemical pathways have 
had modest success; however, events regulated by T cell specific factors may provide a 
more cell specific targeting strategy that would minimize potential off-target gene 
activation. I suggest that T cell restricted transcription factors strongly influence HIV-1 
proviral transcription and that these factors may provide specific targets for eliminating 
latent HIV-1. I report that Blimp-1, a critical regulator of B and T cell differentiation, is 
highly expressed in memory CD4
+
 T cells compared to naïve CD4
+
 T cells and is induced 
following T cell activation. Furthermore, I show that Blimp-1 binds sequences 
downstream of HIV-1 LTR, called HIV-1 ISRE, and is displaced following T cell 
activation. Blimp-1 inhibits Tat-dependent HIV-1 transcription. Reduction of Blimp-1 in 
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infected primary T cells, including CD4
+
 memory T cells, increases RNAP II 
processivity, histone H3 acetylation and baseline HIV-1 transcription. Treatment with 
protease inhibitors (Pacenti et al., 2006) as well as HIV-1 Tat have been shown to 
increase Blimp-1 expression in T cells (Sforza et al., 2014), thus promoting HIV-1 
latency. Therefore, the transcriptional repressor, Blimp-1, is an intrinsic factor that 
predisposes CD4
+
 memory T cells to latent HIV-1 infection. I predict that modulating the 
expression of Blimp-1 or targeting its cofactors would reactivate and potentially purge 
latent virus in specific T cell subpopulations without global T cell activation. However, 
further research is required to understand the Blimp-1-mediated mechanisms of 
repression of HIV-1 transcription in different T cell subsets and to assess which Blimp-1-
interacting factors are the best candidates for the development of novel treatment 
strategies. NELF-induced RNAP II promoter proximal pausing is a common mechanism 
of repressing proviral expression. Further studies are required to elucidate whether RNAP 
II pausing at HIV-1 LTR can be disturbed by modulating intrinsic T cell factors. 
Blimp-1 inhibits Tat-dependent and Tat-independent HIV-1 transcription. Based 
on the latter finding, I would speculate that that Blimp-1 represses the generation of TAR 
RNA, thus inhibiting the recruitment of Tat and P-TEFb to HIV-1 LTR. Blimp-1 has 
been shown to inhibit transcription of c-Myc, a factor implicated in the release of paused 
RNAP II (Lin et al., 1997; Rahl et al., 2010). It remains to be determined if targeting of c-
Myc by Blimp-1 is another mechanism via which Blimp-1 inhibits HIV-1 transcriptional 
elongation and generation of TAR RNA stem loop. Blimp-1 is a transcription factor that 
regulates its target genes by recruiting histone-modifying complexes, such as 
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methyltransferases and HDACs. Decreasing Blimp-1 levels increased acetylation of 
histone H3 at Nuc-1 positioned next to HIV-1 LTR. It remains to be seen if Blimp-1 
recruits histone-modifying enzymes to Nuc-1. Preliminary data shows that treatment with 
TSA, an inhibitor of HDACs I and II, and BIX02194, a G9a inhibitor, did not abolish 
Blimp-1 mediated repression of HIV-1 transcription. However, the experiments should 
contain proper controls verifying that the inhibitors are effective, such as ChIPs looking 
at the acetylation and methylation of Nuc-1. It will be critical to fully characterize the 
mechanism by which Blimp-1 leads to increase in HIV-1 transcription upon T cell 
activation. It may be informative in future studies to look if Blimp-1 recruits LDS1 (Su et 
al., 2009), a histone lysine demethylase, which has been shown to repress HIV-1 
transcription by inducing trimethylation of H3K4 and H3K9 (Le Douce et al., 2012) as 
well as to activate Tat (Sakane et al., 2011). The interaction of Blimp-1 with LSD1 could 
provide a mechanism for Blimp-1-mediated repression of HIV-1 in resting T cells where 
Blimp-1 would recruit LSD1 to methylate histones, and for Blimp-1 mediated induction 
of HIV-1 transcription upon T cell activation where Blimp-1 may recruit LSD1 to Tat to 
activate it.  
I also speculate that Blimp-1 mediated enhancement of HIV-1 transcription upon 
T cell activation may be a result of Blimp-1 inhibiting another transcriptional repressor of 
HIV-1, since upon T cell activation Blimp-1 is no longer bound to provirus. Further 
studies to investigate the induction of HIV-1 transcription by Blimp-1 in activated T cells 
could also investigate the interaction of Blimp-1 with the viral transcriptional activator 
Tat or P-TEFb complex. It remains to be determined why Blimp-1 dissociates from the 
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HIV-1 ISRE upon T cell activation. I show that Blimp-1 co-occupies the HIV-1 ISRE 
with IRF-1 and IRF-8 and that T cell activation leads to a decrease in the binding to this 
site of all of these factors. Thus IRF-1 and IRF-8 do not replace Blimp-1 at the ISRE in 
the HIV-1 LTR upon activation. Future studies investigating the post-translational 
modification of Blimp-1 may provide useful information as to why Blimp-1 is released 
from the HIV-1 ISRE upon T cell activation. Future experiments should look at the 
change in Blimp-1 phosphorylation, ubiquitination and SUMOylation upon T cell 
activation and identify the protein responsible for these modifications. Co-culture of 
HIV-1-pulsed DC with T cells induces the expression of Blimp-1, as well as markers of 
exhaustion, including PD-1, Tim-3, LAG-3 and CTLA-4 (Shankar et al., 2011). 
However, Blimp-1 has been recently shown to repress the expression of PD-1and 
NFATc1, its activator, in CD8
+
 T cells (Lu et al., 2014b). It is also possible that by 
inhibiting NFAT, a transcriptional activator of HIV-1, Blimp-1 contributes to repression 
of HIV-1 transcription. It remains to be determined if Blimp-1 directly regulates the 
expression of other exhaustion molecules in HIV-1 infection. Bach-2 is a repressor of 
Blimp-1 and T cell differentiation (Tsukumo et al., 2013a) that has been shown to be 
enriched for integrated provirus site over time (Ikeda et al., 2007). It is possible that the 
disruption of BACH2 gene by provirus is in part responsible for the induction of Blimp-1 
levels in HIV-1-infected patients.  
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Role of neighboring host genes in HIV-1 transcription 
I also examined the influence of host neighboring promoters on HIV-1 
transcription to identify common mechanisms controlling HIV-1 latency. About 40% of 
human transcripts overlap with each other (Birney et al., 2007) suggesting that 
neighboring promoters affect each other’s expression. HIV-1 integrates into 
transcriptionally active host genes and its transcription is carried out and controlled by 
the host transcriptional machinery. I have shown that inducible cell lines are differentially 
responsive to T cell activation and treatment with HDACs inhibitor. In addition, 
integration of provirus in the convergent orientation resulted in the induction of the host 
gene, while HIV-1 transcription did not correlate with the neighboring host gene 
expression levels. Furthermore, my data indicates that expression of the host gene allows 
HIV-1 transcriptional activation. My research has demonstrated that the majority of 
repressed provirus integrated into host genes in the parallel and convergent orientation 
has NELF and stalled RNAP II at the LTR. Decreasing NELF was able to induce HIV-1 
transcription. My data supports a model in which HIV-1 latency is established and 
maintained by multiple mechanisms, including RNAP II promoter proximal pausing, 
condensed chromatin structure, T cell activation and intrinsic T cell transcription factors 
but is not dependent on proximity or orientation to the neighboring host promoters. 
My data suggests that neighboring promoters have minimal impact on HIV-1 
transcription; however I was not able to modulate the transcription of the host genes to 
definitely rule out their contribution to the maintenance of HIV-1 latency as there is not 
sufficient data looking at regulation of transcription of these host genes. The orientation 
  
88 
of the host genes and HIV-1 LTR does not seem to correlate with a specific 
transcriptional repression mechanism. However, in the cell lines with the convergent 
orientation of promoters the increasing distance between the two promoters seems to 
decrease the level of host gene transcription upon cell activation. It would be intriguing to 
investigate whether increasing the distance between HIV-1 LTR and a convergent 
promoter would increase their transcriptional interference by constructing a plasmid with 
the HIV-1 promoter integrated at different positions in the same gene. Because there was 
a range of responses to TSA treatment among CA5, BA1, 11B10, EF7 and CG3 cells one 
should try another HDAC inhibitor, such as valporic acid or vorinostat. It may be 
informative in future studies to look at the influence of activation with CD3+28 to see if 
signaling downstream of the TCR has different effect on host genes and HIV-1 
expression compared to treatment with PMA+PHA. Future studies should be also aimed 
at measuring the strength of the neighboring host promoter to see if it plays a role in 
repressing HIV-1 transcription. Additional experiments verifying that the host genes are 
transcriptionally active need to be performed. Future studies would benefit from looking 
at the presence of active RNAP II at the host genes by using an antibody specific to 
phosphorylated Ser-2 of RNAP II. Future studies would ideally look at the presence of 
chimeric mRNA messages spanning the upstream host gene and the viral promoter to see 
if the elongating RNAP II disrupts transcriptional machinery at HIV-1 LTR. Because 
HIV-1 latency in inducible cell lines is regulated by a combination of mechanisms it will 
be critical to see if NELF cooperates with Blimp-1 to repress HIV-1 transcription by 
inhibiting RNAP II processivity. 
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Significance and Implications 
My data show that there are common mechanisms mediating HIV-1 latency. 
Blimp-1 represses RNAP II processivity to sequences downstream of the ISRE, while 
proviruses integrated into active neighboring host genes have RNAP II paused at their 
promoters. Both, the inducible cell lines as well as cells expressing high levels of Blimp-
1 have accumulation of short HIV-1 mRNA transcripts showing that RNAP II pausing is 
a common checkpoint of HIV-1 transcription. Previous work from our laboratory showed 
that NELF recruits NCoR1-GPS2-HDAC3 complex to HIV-1 LTR to remodel chromatin 
and induce premature termination of transcripts in primary CD4
+
 T cells (Natarajan et al., 
2013). Thus, RNAP II pausing is coordinating multiple repressive pathways and targeting 
it may help in reactivating latent provirus. 
To eradicate HIV-1 infection it would be preferable to use “shock & kill” 
approach, where latency reversing agents (LRA) would be used to reactivate latent virus 
while the patient is on HAART (Fig. 27). This strategy would result in elimination of 
latent reservoir and cell death of infected cells. Recent studies showed that broadly 
neutralizing antibodies (bNAbs) prevent the establishment of new infections and in 
combination with LRA greatly reduce the chance of viral rebound after cessation of 
treatment (Halper-Stromberg et al., 2014). HIV-1 gene therapy is another promising 
venue, where by using zinc-finger endonucleases (ZFNs) one can disrupt either the genes 
encoding HIV-1 co-receptors or provirus itself (Manjunath et al., 2013). The “shock & 
kill” strategy could benefit from including bNAbs to block new infections and gene 
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therapy to further interfere with HIV-1 replication (Fig. 27). In addition drugs targeting 
NELF or Blimp-1 may aid in the release of paused RNAP II, increase RNAP II 
processivity and open chromatin structure. 
 
Figure 27. "Shock & Kill" Strategy to Cure HIV-1. 
Eradication of HIV-1 infection will require the disruption of HIV-1 latency by using 
LRA. The disruption of latency should co-occur with HAART administration. The 
addition of bNAbs may prevent new infections, while gene therapy may aid in disruption 
of latent provirus that is not responsive to LRA. The goal of the “shock & kill” strategy 
would be reactivation of all latent provirus concurrent with depletion of all infected cells. 
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APPENDIX 
 
RATIONALE 
 
 The Src kinase leukocyte-specific protein tyrosine kinase (Lck) is essential for 
initiating T cell receptor (TCR) signaling by activating downstream signaling proteins, 
such as phosphoinositide 3-kinase (PI3K) which phosphorylates PIP2 to 
phosphatidylinositol-3,4,5-trisphosphate (PIP3) (Cannons and Schwartzberg, 2004). The 
Tec kinase interleukin-2-inducible T cell kinase (Itk) is a critical mediator of cytoskeleton 
rearrangements induced by TCR signaling. Itk is recruited to the PM by binding to PIP3, 
where it is phosphorylated by Lck (Cannons and Schwartzberg, 2004). 
Previously, our lab has identified Lck and Itk as being crucial in efficient HIV-1 
replication. I have shown that Lck positively regulates HIV-1 release, and physically 
interacts with Gag (Strasner et al., 2008). In T cells Gag assembly takes place at the PM, 
but in Lck deficient T cells Gag accumulates in intracellular compartments (Finzi et al., 
2007; Strasner et al., 2008). Itk is required for efficient viral entry, transcription, and 
release (Readinger et al., 2008). I wanted to confirm that Lck increases HIV-1 release by 
regulating multiple stages of Gag intracellular transport and processing. I was especially 
interested in determining whether Lck is involved in transporting Gag to the PM, or 
preventing endocytosis of assembling Gag from the PM. 
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METHODS 
 
For fluorescence microscopy experiments I have generated GFP-tagged WT Lck 
expression construct by using CT-GFP Fusion TOPO TA Expression Kit (Invitrogen). 
293T and HeLa cells were plated on glass coverslips (Fisher). At 16 h post-transfection, 
cells were fixed in 2% paraformaldehyde, incubated with DAPI (Invitrogen), and 
mounted on glass slides. Samples were imaged using a 60x objective on Nikon 
deconvolution wide-field Epifluorescence microscope. Stack of 31 images were collected 
at 0.3-m spacing. Images were deconvolved using 10 iterations with NIS elements 
software. The data analysis was done with NIS elements software. To look at Lck role in 
HIV-1 replication I have generated Jurkat T cell lines with stable Lck knockdown using 
sh-RNA (Dharmacon). For experiments looking at the viral release VLPs were purified 
by pelleting collected supernatants on 20% sucrose gradient at 100,000 xg for 1.5 h at 4 
°C. The HIV-1 concentration in the supernatants was measured using an Alliance HIV-1 
p24 Elisa Kit (Perkin-Elmer). I have used cell fractionation to look at Lck, Itk and Gag 
co-localization in different cellular compartments. Whole cell lysates were run on SDS-
PAGE (12% gel) and western blots were used to detect protein expression. 
 
RESULTS 
 
To test the role of Lck in HIV-1 release I have generated stable, Lck-deficient 
Jurkat cell lines using Lck shRNA. Although in the past our lab had used JCaM cells, 
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which do not express functional Lck, the use of cells in which Lck was knockdown 
represents a more plausible approach to study the effect of Lck on HIV-1 release. 
Examination of virus-infected sh-Lck Jurkat cells confirmed Lck’s role in viral 
replication as the Lck knockdown decreased HIV-1 release by approximately 75% (Fig. 
28). 
  
 To determine if Lck  and Itk are the primary non-receptor tyrosine kinases 
mediating HIV-1 replication I have also examined the role of Fyn. Fyn and Lck are the 
two Src kinases expressed in T cells. I have decreased Fyn expression in Jurkat cells 
using si-Fyn. The knockdown was successful as determined by immunoblots; however, 
Figure 28. Lck is Required for Efficient HIV-1 Replication. 
Jurkat T cells stably transduced with sh-Lck or sh-Ctrl lentivirus were infected with HIV-
1-PLAP-Nef(-) and the release of HIV-1 p24 was monitored over the course of 10 days. 
Whole cell lystes were probed with either anti-HIV-1 p24
gag
, anti-Lck or anti-actin Abs. 
Results shown are from a single experiment with each data point representing three 
independent infections. These data are representative of three experiments. 
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with or without activation with anti-CD3 and -CD28 Abs , there was no significant 
difference in HIV-1 release between si-CTRL and si-Fyn transfected cells as measured by 
p24 release (Fig. 29). Thus, Lck is the primary Src kinase required for efficient HIV-1 
particle release from infected T cells. 
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Figure 29. Fyn has Minimal Impact on HIV-1 Replication in T Cells. 
Jurkat cells were electroporated with si-CTRL or si-Fyn, and infected 24 h post 
transfection with HIV-1-PLAP-Nef(+). Cells were activated with 0.1 µg/ml anti-CD3 and 
1 µg/ml anti-CD28 Abs for 24 h before collection. Release of p24
gag
 was monitored at 
days 3 and 5 post-infection. Whole cell lysates were probed with anti-Fyn and anti-actin 
Abs. 
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Previously our lab has shown that Lck promotes Gag assembly at the PM 
(Strasner et al., 2008).I have now demonstrated that in 293T (Fig. 30) and in HeLa cells 
(Fig. 31) Lck co-localizes with Gag at the PM and in intracellular compartments. 
Mutation of the basic region in the MA domain leads to redistribution of Gag and its 
intracellular accumulation in late endosomes (Chukkapalli et al., 2008; Ono and Freed, 
2004; Zhou et al., 1994). I speculated that expression of Lck may redirect the mutant Gag 
to the PM through a direct interaction with it. To test this I used Δ-MA-Gag, which has a 
deletion of residues 15 through 99 in the basic region of MA domain. However, using 
fluorescent imaging I observed that Δ-MA-Gag was located in intracellular 
compartments, even in the presence of Lck. This data suggest that Δ-MA-Gag has altered 
trafficking and thus does not interact with Lck, because it is not present in the same 
subcellular compartments as Lck, or that Lck binds to the MA domain of Gag. 
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Figure 30. Lck Co-localizes with Gag at the PM and in Intracellular Compartments. 
293T cells were plated onto glass coverslips and transfected (A) or cotransfected (B) with 
Lck, and Gag-cherry as indicated. 16H post-transfection cells were washed with PBS and 
then fixed with 2% paraformaldehyde and stained with antibody to Lck. The glass 
coverslips were mounted onto glass slides and viewed using a Nikon fluorescence 
microscope at 60x immersion and deconvoluted using 10 iterations with NIS elements 
software. 
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Figure 31. Lck Alters the Localization of Gag in HeLa Cells. 
HeLa cells were plated onto glass coverslips and transfected (A) or cotransfected (B) 
with Lck-GFP and Gag-Cherry, as indicated. 72H post-transfection cells were washed 
with PBS then fixed with 2% paraformaldehyde. The glass coverslips were mounted onto 
glass slides and viewed using a Nikon fluorescence microscope at 60x oil immersion and 
deconvoluted using 10 iterations with NIS elements software. 
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Figure 32. Lck Does Not Alter the Intracellular Accumulation of ΔMA-Gag. 
293T cells were plated onto glass coverslips and transfected with ΔMA(15-99)-Gag-
Cherry (A), or cotransfected with Lck and ΔMA-Gag-Cherry (B). 16H post-transfection 
cells were washed with PBS and then fixed with 2% prafaformaldehyde and stained with 
anti-Lck Ab. The glass coverslips were mounted onto glass slides and viewed using a 
Nikon fluorescence microscope at 60x oil immersion and deconvolved using 10 iterations 
with NIS elements software. 
Figure 20. Lck is not able to rescue the intracellular accumulation of ΔMA-Gag. 
293T cells were plated onto glass coverslips and transfected with ΔMA(15-99)-Gag-Cherry (A), or cotransfected with 
Lck and ΔMA-Gag-Cherry (B). 16H post-transfection cells were washed with PBS and then fixed with 2% 
prafaformaldehyde and stained with anti-Lck Ab. The glass coverslips were mounted onto glass slides and viewed 
using a Nikon fluorescence microscope at 60x oil immersion and deconvolved using 10 iterations with NIS elements 
software. 
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The assembly of HIV-1 occurs at the PM in T cells and macrophages, though 
some studies have suggested that intracellular compartments in macrophages can support 
virus assembly (Ono and Freed, 2004). However, as a result of frequent endocytosis Gag 
is also found in late endosomes in cells with preferential Gag assembly at the PM (Finzi 
et al., 2007; Klein et al., 2007; Ono and Freed, 2004). Clathrin- and cholesterol-
dependent endocytosis of Gag along microtubules is mediated by dynamin (Cannons and 
Schwartzberg, 2004; Klein et al., 2007). To identify the function of Lck in preventing 
intracellular Gag accumulation I treated cells with Dynasore, a dynamin inhibitor, to 
block dynamin-dependent endocytosis. The treatment of 293T cells transfected with Gag, 
as well as Jurkat cell lines infected with HIV-1 with Dynasore did not change the fold 
induction of released p24 mediated by Lck (Fig. 33 and 34). These data suggests that 
Lck does not prevent endocytosis of Gag, or that HIV-1 is not endocytosed via a dynamin 
dependent pathway. Clathrin- and dynamin-dependent endocytosis are the two major 
endocytic pathways. To assess whether Lck prevents nascent virus endocytosis future 
studies would benefit from including Chlorpromazine to inhibit the clathrin- dependent 
endocytosis. Further studies investigating whether Lck inhibits the endocytosis of Gag 
should also include live cell microscopy of cells transfected with Gag-Cherry and Lck-
GFP. The movement of Gag at the PM may be visualized by fluorescence recovery after 
photobleaching (FRAP), where regions beneath the PM associated with Gag-Cherry 
would be photobleached and monitored for subsequent recovery of Gag-Cherry. 
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The free diffusion of Gag from cytosol to the PM is prevented by densely packed 
cytoplasm and HIV-1 has to use the cellular transport system to ensure successful exit 
from the cell (Naghavi and Goff, 2007). Transport of Gag RNA, as well as Pr55Gag to 
the PM is microtubule dependent (Mouland et al., 2001). To test whether Lck-mediated 
VLPs release is actin and microtubule dependent, I co-transfected 293T cells with Gag 
and Lck or infected stable Jurkat cell lines with HIV-1 and blocked cytoskeleton 
reorganization with different inhibitors. Latrunculin B- and Cytocholasin-D-mediated 
inhibition of actin polymerization interfered with viral release, but did not block Lck-
mediated enhancement of VLPs and HIV-1 release (Fig. 34 and 35). The treatment of 
Figure 33. Lck Mediated Virus Like Particles Release is Dynamin Independent. 
293T cells were transfected with Gag along with Lck or pcDNA3.1 vector control via 
calcium phosphate.  3 h after transfection new media with 2 and 10 µM Dynasore or 
DMSO was added to cells.  72 h after transfection supernatants were collected, spun on 
20% sucrose cushion and analyzed for p24 via ELISA. 
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cells with Nocodazole, a microtubules polymerization inhibitor, did not impede the 
release of virus like particles, both in the presence and absence of Lck (Fig. 34). The 7 
day treatment of Jurkat cells with Nocodazole was toxic to the cells (Fig. 35). These data 
suggest that Lck mediated enhancement of HIV-1 release does not depend on 
cytoskeleton reorganization. Additional experiments should be performed using a 
microtubule depolymerization inhibitor (taxol) to rule-out the potential contribution of 
microtubules in Lck-mediated HIV-1 release.  
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Figure 34. Lck Mediated Virus Like Particles Release Does Not Require 
Cytoskeleton Reorganization. 
293T cells were transfected with Gag along with Lck or pcDNA3.1 vector control via 
calcium phosphate. 3 h after transfection new media with 2.5µM Cytocholasin D, 2.5µM 
Latrunculin B and 10 µg/ml Nocodazole or DMSO was added to cells. 72 h after 
transfection supernatants were collected and analyzed for p24 via ELISA. 
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Rab proteins are small GTPases controlling vesicular trafficking (Saftig and 
Klumperman, 2009). One such protein, Rab11, is located on the cytosolic face of 
perinuclear recycling endosomes and controls the trafficking of vesicles from TGN and 
recycling endosomes to the PM (Saftig and Klumperman, 2009). Src kinases are present 
on clathrin-independent vesicles that recycle back out to the PM dependent on Rab11 and 
actin (Donaldson et al., 2009). The exit of Lck from Rab11 positive endosomes requires 
the activation of Rab11 by the adaptor protein Uncoordinated 119 (Unc119), which is 
present in Rab-11 positive endosomes (Gorska et al., 2009). Rab11 enhances HIV-1 
release, and its deficiency results in an intracellular accumulation of Gag, and in a 
decreased HIV-1 release (Amet et al., 2008; Saftig and Klumperman, 2009). Because Lck 
Figure 35. Lck Mediated HIV-1 Replication Is Not Abolished by Cytoskeleton and 
Dynamin Inhibitors. 
sh-Control and sh-Lck Jurkat stable cell lines were infected with HIV-1-PLAP-Nef(+).  8 
h post-infection new media with inhibitors were added to the cells.  7 days post-infection 
the supernatants were collected and analyzed for p24 via ELISA. 
  
105 
and Gag require Rab11 to be conveyed to the PM, it is conceivable that they both follow 
similar trafficking route (Amet et al., 2008; Gorska et al., 2009).  To examine the effect 
of altering Lck trafficking on Gag release I have transfected 293T cells with Gag, Lck, 
Rab11 (Gorska et al., 2009) and Unc119 (Gorska et al., 2009) via calcium phosphate. 
Supernatants were collected 72 h post-transfection, VLPs purified and analyzed for p24 
via ELISA. The overexpression of Rab11 alone did not affect VLPs release (Fig. 36), 
even though it has been previously shown to inhibit perinuclear accumulation of Gag 
(Amet et al., 2008). Additionally, over-expression of Rab11 slightly decreased Lck-
mediated VLPs release (Fig. 36). One might expect that Unc119 increases VLPs release 
by inducing Lck to activate Abl leading to actin reorganization, as well as inhibiting 
dynamin-dependent endocytosis (Gu et al., 2009; Karim et al., 2010).However, 
overexpression of Unc119 also did not increase viral release and decreased Lck-mediated 
enhancement (Fig. 36). One possible explanation for these negative data may be the fact 
that in 293T cells Gag is transported to the PM even in the absence of Lck (Fig. 30). 
Future experiments should be performed in HeLa or preferably in T cells and use siRNAs 
to deplete Rab11 and Unc119 or dominant-negative forms of Rab11 and Unc119. 
Alternatively, Lck trafficking might be also altered by manipulating the expression of 
MAL protein (Anton et al., 2008). 
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Lck orchestrates T cell signaling by phosphorylating downstream proteins. To 
determine if Lck needs to be active to enhance HIV-1 replication I have treated Jurkat 
cells with Damnacanthal, a specific Lck autophosphorylation inhibitor, and PP2, a Src 
family inhibitor. There was no significant difference between the unstimulated cells 
treated with Damnacanthal and PP2 compared to the control cells (Fig. 37).  However, 
stimulated cells treated with Damnacanthal and PP2 showed even greater amounts of 
HIV-1 being released than the control cells (Fig. 37). This suggests that the activation of 
Figure 36. Rab11 and Unc119 do not Increase VLPs Release. 
293T cells were transfected with Gag along with Lck, Rab11, Unc119 or pcDNA3.1 
vector control via calcium phosphate. 72 h after transfection, supernatants were collected, 
spun on 20% sucrose cushion and analyzed for p24 via ELISA. 
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Lck is dispensable for efficient HIV-1 replication.  These results support the previous 
data showing that the kinase dead Lck induces virus like particles release more efficiently 
than the wild type Lck (Strasner et al., 2008), suggesting that Lck may be acting as an 
adapter protein for Gag assembly. 
 
 
 
Lck and Itk are both T cell specific non-receptor tyrosine kinases that participate 
in T cell signaling, and enhance HIV-1 release (Readinger et al., 2008; Strasner et al., 
Figure 37. Activation of Lck is Not Required for Efficient HIV-1 Replication. 
Jurkat cells were pre-treated with kinase inhibitors for 1 hour, and infected with HIV-1-
PLAP-Nef(+) in the presence of inhibitors.  12 h post-infection the new media with 
inhibitors was added to the cells.  The cells were left unactivated (A) or activated with 
anti-CD3 and 28 Abs for 24h (B).  At 7 days post-infection the supernatant was collected 
and analyzed for p-24 via ELISA.  Whole cell lysates were probed with anti-pLck 
(Tyr505) Ab. 
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2008). Consistent with previous reports the non-receptor tyrosine kinases Lck and Itk 
increased VLPs release (Fig. 38). Additionally, the co-transfection of Gag with Lck and 
Itk showed that Lck and Itk cooperatively interact to enhance VLPs release (Fig. 38). 
These data suggests that Lck and Itk functionally interact with each other to achieve 
optimal HIV-1 release. The synergistic effect between Lck and Itk on HIV-1 release 
should be confirmed in T cells by performing double knockdown of Lck and Itk. 
 
To identify intracellular compartments in which Gag and Lck interact, and the 
route that they follow to the PM I used subcellular fractionation. sh-Lck and sh-CTRL 
Jurkat cells were infected for 24 h with HIV-1. Cells were homogenized 5 days post-
infection, and separated using subcellular fractionation into 13 fractions, with fractions 1-
Figure 38. Lck and Itk Co-operate to Enhance Gag Release. 
293T cells were transfected with Gag along with Lck, Itk or pEGFP vector control via 
calcium phosphate.  72 h after transfection, supernatants were collected, spun on 20% 
sucrose cushion and analyzed for p24 via ELISA. 
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5 predicted to represent lipid rafts (Triantafilou et al., 2002). Gag co-localized with Lck 
in fractions 2-5 (Fig. 40). As expected, cells stably expressing sh-Lck had overall reduced 
levels of Lck and Lck was present only in fractions 2-4 instead of 1-5 (Fig. 40). The 
reduction of Lck levels also resulted in decreased presence of Itk in fractions 2-5 (Fig. 
39). These results suggest that the subcellular localization of Itk is Lck dependent. In the 
subcellular fraction experiment the different fractions should be probed with Abs for 
markers of lipid rafts (GM1), non-raft associated proteins (CD45), early endosomes 
(EEA1and Rab5), late endosomes (Lamp1 and TGN), as well as Rab11 and Unc119, 
proteins controlling the trafficking and activation of Lck. 
The above experiments do not provide definitive mechanism by which Lck 
enhances Gag release. All experiments with inhibitors should be better controlled, 
account for possible cell death and preferentially the cytoskeleton should be visualized 
using microscopy. 
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Figure 39. Lck Co-Fractionates with Gag in Lipid Rafts. 
A) The experimental workflow used for subcellular fractionation of HIV-1-infected cell 
lines. B) Jurkat T cells stably transduced with sh-Lck or sh-Ctrl lentivirus were infected 
with HIV-1 for 7 days. Cells were lysed in buffer A containing 0.25% Triton X-100 at 
4°C and the lysate was mechanistically disrupted. Lysates were mixed with one volume 
of 50% OptiPrep and centrifuged at 52,000 xg for 16 h at 4 °C. Thirteen fractions were 
collected from the top of the gradient, and analyzed by western blot. Fractions 1-5 are 
predicted to contain lipid rafts (Triantafilou et al., 2002). 
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